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ABSTRACT 
 Arguably a population with the greatest unmet need for therapies is pregnant women. 
Despite the risk of maternal and offspring perinatal morbidity and “programming” of adult 
disease in the offspring, there is a lack of therapies for treating pregnancy disorders. As many 
pregnancy disorders involve uteroplacental hypoxia, high-altitude (HA, > 2500m) pregnancy is 
an effective model in which to isolate effects of hypoxia during pregnancy to address 
mechanisms by which uteroplacental hypoxia might be therapeutically treated. HA pregnancy is 
associated with reduced uterine artery blood flow and fetal growth, and thus recapitulates 
disorders of pregnancy such as intrauterine growth restriction (IUGR). The AMPK and PPARg 
pathways are attractive molecular targets for improving uterine artery blood flow in hypoxic 
pregnancy, as both have vasodilatory effects and their expression has been associated with 
protected fetal growth at HA, while loss of the expression of PPARg has been associated with 
IUGR. We hypothesized that pharmacologic activation of AMPK or PPARg would improve 
uterine artery and placental perfusion and protect fetal growth in hypoxic disorders of pregnancy. 
To address this hypothesis, mice were exposed to late-gestation hypoxia sufficient to induce 
IUGR. The mice were treated with AICAR or Compound C (ComC) to activate or inhibit 
AMPK, respectively, or pioglitazone (PIO) to activate PPARg. Treatment with AICAR partially 
prevented fetal growth restriction, due in part to a rise in blood flow, selectively in the uterine 
artery, and increased placental efficiency. Treatment with PIO fully prevented fetal growth 
 iv 
restriction despite a reduction in placental vascularity. Ex vivo activation of AMPK or PPARg 
using A769662 or troglitazone, respectively, vasodilated isolated uterine arteries from mice 
exposed to hypoxia and normoxic controls. Our findings indicate that activating the AMPK and 
PPARg pathways was sufficient to protect fetal growth in a model of hypoxia-induced IUGR, 
likely by improving uterine artery vasodilation thereby increasing nutrient and oxygen delivery 
to the fetus. These data implicate reduced uterine artery blood flow in HA pregnancy as a 
promising physiological target for improving fetal growth and implicate AMPK and PPARg as 
potential molecular pathways for doing so. 
 
The form and content of this abstract are approved. I recommend its publication. 
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INTRODUCTION AND BACKGROUND 
Introduction  
 Complications of pregnancy such as intrauterine growth restriction (IUGR) represent an 
important public health problem. Fetal hypoxia, which adversely affects fetal growth, is a 
common feature of several pregnancy complications, including intrauterine growth restriction 
(IUGR), affecting up to 10% of pregnancies (1); gestational diabetes mellitus, which affects up 
to 9% of all USA pregnancies (2); preeclampsia (PreE), affecting up to 8% of pregnancies (3); 
inflammatory diseases during pregnancy (4); high-altitude (HA, >2500 m) pregnancy; and in 
overweight or obese pregnancy, occurring in at least 45% of pregnancies (5). Identifying 
therapeutic targets to alleviate fetal hypoxia is therefore necessary. Fetal hypoxia is often 
accompanied by maternal and/or placental vascular abnormalities and decreased uterine blood 
flow, making it difficult to know whether hypoxia is a cause or a consequence of the pregnancy 
disorder. There are currently no therapies for treating IUGR or similar pregnancy disorders 
involving fetal hypoxia. This is due in part to a need for better understanding of healthy maternal 
responses to pregnancy and how these processes are affected by insults like hypoxia of HA 
residence.  
 In this chapter, I will introduce the significance of my thesis work and the AMPK and 
PPARg signaling pathways on which I focused and provide context for the next four chapters. 
Developmental Origins of Adult Disease 
In 1990, the British epidemiologist David Barker proposed the hypothesis that IUGR 
birth has a causal relationship to later-life adult diseases including hypertension and coronary 
heart disease (6). This hypothesis is now known at the “Barker hypothesis” and is referred to as 
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“fetal programming” or the “developmental origins of adult disease.” A massive amount of 
literature supports this hypothesis, providing correlative and mechanistic evidence for a link 
between low birth weight and increased risk for many adult diseases including cardiovascular 
disease, diabetes, obesity, and hypertension (7, 8). Studies have shown that long-term effects on 
the offspring might be conferred via tissue remodeling (9), maternal-fetal endocrine exchange 
(10, 11), or epigenetic changes (12). HA is a risk factor for IUGR and pregnancy at HA increases 
cardiac and peripheral vascular dysfunction during adulthood in experimental animals (13) and 
susceptibility to Chronic Mountain Sickness in humans, a syndrome characterized by excessive 
polycythemia often leading to pulmonary hypertension and right heart failure (14-16). The 
consequence of pregnancy resulting in diminished birth weight, therefore, not only puts the 
mother and baby at risk of perinatal morbidity and mortality, but also increases morbidity of the 
offspring later in life. These points highlight the importance of developing safe and effective 
therapies for improving fetal growth in cases of IUGR. We focus on evaluating HA exposure 
during pregnancy and possible mechanisms for improving fetal growth, in order to improve 
perinatal and long-term health outcomes for the mother and baby (Fig. I.1). 
High Altitude as a Research Model 
HA studies have advanced the understanding of maternal physiologic responses to 
pregnancy which are necessary for fetal growth and are disrupted in IUGR. Studying HA 
pregnancy for the sake of improving HA pregnancy outcomes is important, as at least 4 million 
women residing at HA are pregnant at any given time, and the chronic hypoxia of residence at 
HA has potent adverse effects on maternal, fetal, and neonatal well-being. Specifically, the 
frequency of PreE and IUGR is 3-fold greater at HA (17-20). Doppler indices of fetal brain 
sparing and the greater reduction in newborn weight than length indicate that hypoxia-induced 
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IUGR, rather than the babies being constitutionally small, is the principal cause of the lower 
birth weights at HA (21, 22). These points implicate maternal hypoxia itself in the reduction of 
fetal growth in the absence of other pathologies.  
Complications of pregnancy at low altitude involving hypoxia are also a major public 
health problem. IUGR raises neonatal mortality 8 to 20-fold and PreE accounts for 40% of fetal 
and 18% of maternal deaths at low altitude (23, 24). 
The Moore lab group has extensively studied pregnant women residing at HA and 
evaluated the isolated effects of hypoxia on human pregnancy. Dr. Moore and colleagues have 
observed that populations living at HA for many generations, including Tibetans and Andeans, 
are protected from IUGR induced by hypoxia of HA residence compared to newcomers at high 
elevations, such as Han Chinese and Europeans (25-29). These studies allowed for identification 
of genetic factors contributing to resistance to hypoxia-induced IUGR, including SNPs in the 
AMPKa1 gene region predicted to activate AMPK, which was elevated in the Andean population 
(30) and associated with improved uterine artery blood flow and fetal growth (31). A similar 
study also reported effects of HA on PPARg expression. In HA pregnancy, expression of key 
PPARg pathway genes were downregulated in maternal peripheral blood cells, and this 
correlated with reduced birth weight (32).  
Our data provide evidence that natural selection at HA, including the genetic changes 
proposed to increase expression of AMPK and PPARg, has operated on standing variation rather 
than novel mutations (33-35); therefore, the mechanisms affected are not unique to HA 
populations and can be modulated in other populations as well. Thus, HA studies are poised to 
identify therapeutic targets that will be relevant for HA-induced IUGR as well as cases of IUGR 




Figure I.1. Fetal Programming Schematic. Risk of adult disease is programmed beginning in 
fetal and neonatal life, in which developmental plasticity is high, allowing for environmental 
insults to affect development and long-term health. If offspring are exposed to environmental 
insults, they will be more sensitive to a “second hit” later in life. Early interventions are the most 







Figure I.2. Mechanisms of Action of AMP-Activated Protein Kinase. AMPK is activated by 
an increased ratio of AMP to ATP, as occurs in nutrient or oxygen deprivation. It is also directly 
activated by CaMKK, LKB1, and thiazolidinediones. P-AMPK has many effects, including 
upregulation of eNOS, and downregulation of mTOR complex 1, insulin resistance, and ROS. 
(Adapted from Lee, WH and Kim, SG, AMPK-Dependent Metabolic Regulation by PPAR 
Agonists. PPAR Res, 2010.)  
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 Experimental animal models have been used by many groups to determine the effects of 
gestational hypoxia on fetal growth and the roles of maternal metabolic (36), cardiovascular (37-
39), and placental (40, 41) factors. These models recapitulate the effects of hypoxia of HA 
residence in reducing fetal growth. 
Potential Therapeutic Targets in IUGR 
Adenosine Monophosphate-Activated Protein Kinase 
AMPK is a central metabolic regulator controlling the balance between catabolic and 
anabolic processes in times of stress (42-45). Targeting AMPK with drugs such as metformin has 
been useful in type II diabetes and obesity (46). AMPK has also been shown to have anti-
tumorigenic effects (47-49). However, while its anti-proliferative actions of downregulating 
mechanistic target of rapamycin complex 1 (mTORC1) and RNA polymerase I-specific 
transcription initiation factor RRN3 (TIF-1A) (50-52) are effective in treating cancer, it also is 
protective from nutrient deprivation and hypoxia and thus is not an ideal treatment for cancer. An 
additional role for AMPK is in maintaining cellular homeostasis through autophagy and 
mitophagy (53-55). Figure I.2 summarizes the major actions of AMPK. 
 AMPK is a heterotrimeric complex consisting of alpha, beta, and gamma subunits. Each 
subunit has two or more isoforms which are differentially expressed in certain tissues, potentially 
providing specificity of pharmacologic targets. The alpha subunit contains the catalytic kinase 
domain which imparts AMPK’s ability to phosphorylate downstream targets (56). In vascular 
smooth muscle and endothelium, AMPK complexes contain the alpha1 subunit (57, 58). 
Emerging evidence identifies AMPK as a vasoregulator, contributing to the vasoprotective 
effects of drugs such as metformin (59). With metformin, the effects of AMPK are likely due in 
part to upregulation of nitric oxide production; however, using L-NAME to inhibit nitric oxide 
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synthase, a group found that AMPK’s effects were also directly on vascular smooth muscle cells 
(60). Vasodilatory effects of AMPK have been shown by studies in experimental animal models 
(60, 61) and activating AMPK induced vasodilation in isolated murine uterine arteries (39).  
Peroxisome Proliferator-Activated Receptor Gamma 
 PPARg is a ligand-activated transcription factor of the nuclear hormone receptor 
superfamily that governs gene expression by forming a heterodimeric complex with the retinoid 
X receptor at the regulatory region in target genes. While predominantly recognized for its role 
in metabolic homeostasis (62), PPARg is vital for establishing the uteroplacental villous 
circulation (63, 64) and regulating placental vascularization in early pregnancy (65). 
 PPARg affects vasoreactivity by suppressing the synthesis of the potent vasoconstrictor 
endothelin-1 (66, 67) and increasing nitric oxide production (68, 69). PPARg is likely an 
importantly regulator in physiological responses to pregnancies, since it is abundantly expressed 
in the labyrinthine zone of the rodent placenta (70) and downregulated in human IUGR (32). 
 Drugs that activate PPARg, the class of thiazolidinediones, are used clinically for 
indications such as diabetes and polycystic ovarian syndrome, which makes PPARg an attractive 
therapeutic target for preclinical studies to improve fetal growth in hypoxic pregnancy. 
Scope of Thesis 
 The goal of this thesis work is to evaluate the possibility for AMPK and PPARg pathways 
to be therapeutic targets in improving fetal growth in hypoxic pregnancy. The first hypothesis of 
this work is that AMPK activation is beneficial in the uterine artery and placenta in improving 
blood flow and nutrient delivery to the fetus, insofar as its upregulation would be beneficial for 
fetal growth in hypoxic pregnancy. The second hypothesis of this work is that PPARg activation, 
through its regulation of vascularization and vasodilation, is an effective strategy for improving 
 7 
fetal growth in cases of reduced uteroplacental perfusion. To test these hypotheses, I used a 
mouse model of late-gestation hypoxia-induced IUGR. I first determined the effects of hypoxia 
on uteroplacental signaling and on ex vivo AMPK or PPARg activation effects on uterine artery 
vasoreactivity. Then, I pharmacologically activated AMPK or PPARg in our model of hypoxia-
induced IUGR to determine its effects on fetal growth and uteroplacental function. Chapter 2 
profiles effects of hypoxia on fetal and placental growth; uterine artery volumetric flow, 
vasodilation in response to ex vivo AMPK activation, and structure; and uterine artery and 
placental AMPK activation. Chapter 3 identifies effects of in vivo pharmacologic AMPK 
activation or inhibition and hypoxia on fetal and placental growth, uterine artery volumetric 
flow, and uterine artery contractility. Chapter 4 evaluates the effects of hypoxia on fetal growth, 
the ability of ex vivo PPARg activation to both vasodilate and blunt constriction of the uterine 
arteries, and the levels of PPARg downstream signaling in the placenta. Chapter 5 determines the 
effects of hypoxia and in vivo pharmacologic PPARg activation on fetal and placental growth, 
placental signaling, and placental vascularization. Chapter 6 provides a summary of my thesis 
work and avenues of future work for establishing AMPK and/or PPARg manipulation as 
therapeutic strategies for disorders of pregnancy.  
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CHAPTER II 
INCREASED UTERINE ARTERY BLOOD FLOW IN HYPOXIC PREGNANCY IS NOT 
SUFFICIENT TO PREVENT FETAL GROWTH RESTRICTION1 
Introduction 
Maternal vascular responses to pregnancy are crucial contributors to both short- and long-
term outcomes for both the mother and infant (8, 71). During normal pregnancy, uterine artery 
blood flow increases at least 20-fold (21), thus serving to maintain adequate nutrient and oxygen 
delivery to the developing fetus (72). Insufficient oxygen delivery to the uteroplacental 
circulation and fetal hypoxia adversely affect fetal growth and are common features of the “great 
obstetrical syndromes” (73), including preeclampsia and intrauterine growth restriction (IUGR). 
Despite the well-established links between impaired maternal vascular adaptation to pregnancy 
and poor pregnancy outcomes, the molecular mechanisms governing uteroplacental blood flow 
are not well understood.  
The chronic hypoxia of residence at high altitude (HA, > 2500m) is among the many 
causes of IUGR and incomplete maternal vascular responses to pregnancy. In humans, HA 
residence shifts the entire birthweight distribution leftward, increasing the incidence of IUGR 
three-fold (17, 18). Likewise, hypoxic exposure induces fetal growth restriction in experimental 
animal models. In human (74, 75) and experimental animal models (76, 77), hypoxia-induced 
IUGR appears to result, in part, from incomplete maternal vascular adaptation to pregnancy. 
More than 140 million persons live at HA worldwide (78), of which 4+ million are likely 
pregnant at any one time, thereby providing a natural laboratory in which to study the 
                                               
1Chapter II was taken in its entirety with permission from: Lane (Coates), SL et al., Biology of 
Reproduction, In Review. 
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physiologic and molecular links between uteroplacental hypoxia and fetal growth restriction in 
the absence of overt pathology. For this reason, we and others have used HA as a study design 
with which to address the mechanisms by which hypoxia influences maternal physiological 
adaptation to pregnancy and fetal growth (79-82). 
Our prior work implicates the AMP-activated protein kinase (AMPK) pathway—a key 
metabolic regulator and vasodilator—in the regulation of fetal growth under hypoxic conditions. 
Specifically, Andeans HA residents, who are relatively protected from HA-induced fetal growth 
restriction (22, 26, 28), possess a higher frequency of gene variants predicted to activate AMPK 
and whose presence was associated with greater uterine artery diameter, implying greater blood 
flow, and less altitude-associated reduction in infant birth weight (31). While such variants were 
present at a greater frequency in Andeans, they were not unique to the Andean population. Since 
other factors (e.g., drugs such as metformin and nutritional substances such as resveratrol) can 
activate AMPK, AMPK activation could be a strategy for increasing uterine artery blood flow 
and improving fetal growth in any population. The NIH and other agencies have called for new 
drugs for treating pregnancy pathologies given that there has been limited development of drugs 
which are both safe and effective during pregnancy. 
We focus on the potential therapeutic role for AMPK signaling since its activation is an 
ex vivo vasodilator of the murine uterine artery (39), a drug—metformin—which activates 
AMPK has been approved for use in pregnancy (83), and AMPK activation may be a contributor 
to the protection afforded Andean highlanders from hypoxia-associated fetal growth restriction. 
Here, we aimed to 1) characterize the effects of hypoxia on the vasodilatory effects of AMPK 
activation and on levels of uterine artery and placental AMPK activation and 2) determine the 
role of uterine artery blood flow in hypoxia-induced, late-onset fetal growth restriction. We 
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hypothesized that the hypoxia-induced reduction of fetal weight was due in part to reduced 
uterine artery blood flow resulting from increased uterine artery contractility and/or decreased 
vasodilator response, and that these uterine artery changes would be correlated with reduced 
AMPK activation. Therefore, we exposed pregnant mice to hypoxia or normoxia during the 
period of rapid late-gestational fetal growth. We undertook studies to characterize the effects of 
hypoxia exposure on uterine artery vasoreactivity ex vivo by wire myography, uterine artery 
blood flow in vivo using Doppler ultrasound, and AMPK activation in uterine arteries and 
placenta. 
Materials and Methods 
Animals and Study Conditions 
C57Bl/6 mice were obtained from Charles River (Wilmington, MA). Female mice (20-
25g) were mated with males overnight, with a copulatory plug interpreted as evidence of 
successful breeding at embryonic day (E) 0.5. Animals were housed at the University of 
Colorado’s animal facility altitude (Aurora, 1611 m) until E14.5, when the pregnant mice were 
placed either in hyperbaric (PB ~ 760 mmHg; 0 m) or hypobaric (PB ~ 385 mmHg; 5500 m) 
chambers to simulate normoxia or hypoxia, respectively. Dam body weights were obtained at 
E0.5, E14.5, and E18.5, and food intake measured during the period of normoxic or hypoxic 
exposure. Animals were euthanized by carbon dioxide asphyxiation and cervical dislocation at 
E18.5 (term = 19.5 days). Right and left uterine arteries were excised, and either used 
immediately for myography or placed in 4% paraformaldehyde overnight and paraffin embedded 
within 24h for histological sectioning. Fetuses and placentas were excised from membranes and 
weighed, and placentas were immediately either placed in 4% paraformaldehyde overnight and 
paraffin embedded for sectioning within 24h for histological sectioning, or flash frozen for 
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protein analysis. All animal procedures and protocols were completed in accordance with NIH 
Guide for the Care and Use of Laboratory Animals (84) and were approved by the Institutional 
Animal Care and Use Committee at the University of Colorado. 
Doppler Ultrasound 
Doppler ultrasounds were performed in the Cardiovascular Pre-Clinical Core at the 
University of Colorado-Denver Anschutz Medical Campus (1611 m) on E17.5 pregnant mice 
while breathing room air and under 1-2% isoflurane anesthesia using a 30-MHz pulsed Doppler 
system (Vevo 2100, Visual Sonics, Toronto, ON). Aortic stroke volume and heart rate were 
measured to calculate cardiac output (stroke volume in µl/min x heart rate in bpm). The uterine 
artery was identified at the point where it appears to cross over the external iliac artery. Uterine 
artery peak systolic velocity, end diastolic velocity, and mean velocity were determined by 
manually tracing and then averaging the values obtained from waveform tracings of good quality 
from three consecutive cardiac cycles. Uterine artery pulsatility index (PI) was calculated as 
(systolic–diastolic velocity)/systolic velocity. Uterine artery diameter was approximated using B-
mode color Doppler. While B-mode color may have exaggerated the actual dimension, such an 
effect was considered uniform across animals and thus enabled comparisons of uterine artery 
volumetric blood flow, calculated as p x uterine artery radius2 x uterine artery mean velocity. 
One uterine artery was chosen at random for study so volumetric uterine artery blood flow was 
multiplied by two to approximate the total uterine artery blood flow. The uterine artery index 
was calculated as total uterine artery blood flow/cardiac output to determine the portion of 




Uterine Artery Wire Myography 
Immediately following euthanasia, one or both main uterine arteries were isolated in ice-
cold PBS, cleaned of connective tissue, and cut into 2 mm segments. Segments were mounted 
using 2 stainless steel 40 µm wires for each chamber of a 4-channel, small vessel wire myograph 
(Danish Myo Technology 610M, Aarhus, Denmark). The mounted vessels were continuously 
maintained at 37°C and oxygenated (95% O2/5% CO2; Airgas, Radnor, PA) while submerged in 
Krebs solution (118.5mM NaCl, from Sigma Aldrich, St. Louis, MO; 25mM NaHCO3, 4.75mM 
KCl, 1.2mM MgSO47H20, 1.2mM KH2PO4, 2.5mM CaCl2, 11.1mM D-Glucose, all from Thermo 
Fisher Scientific, Waltham, MA). After a 30-minute equilibration, the vessels were normalized to 
an internal diameter of 0.9 of L13.3kPa, and this diameter was maintained for the rest of the 
protocol. Vessels were then equilibrated for another 30 minutes before vasoreactivity studies 
began. 
Viability was demonstrated by contractile responses of at least 2 mN to 60 mM potassium 
chloride (KCl) and 10 µM phenylephrine (PE; Sigma-Aldrich), and intact endothelium was 
demonstrated in pre-constricted vessels by an 80% or greater vasodilator response to 1 µM 
acetylcholine (ACh; Acros Organics, Pittsburgh, PA). The full contractile response to PE was 
determined across a 1 nM-100 µM range and repeated after incubation with the AMPK agonist 
A769662 (30 µM; Tocris Bioscience, Bristol, UK) to determine the effects of AMPK activation 
on PE contraction. PE response curves were normalized to the maximum KCl response to control 
for the length of each uterine artery segment being studied. Relaxation directly by AMPK 
activation was tested by first contracting the vessels with a submaximal (80% of maximal) PE 
concentration and then determining the response to increasing concentrations of A769662 (1-100 
µM). To determine the contribution of nitric oxide synthase and cyclooxygenase products to the 
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relaxant effects of A769662, the response to A769662 was tested after incubation with 10 µM L-
NAME (BioVision Inc., San Francisco, CA) alone or together with 10 µM indomethacin (Sigma 
Aldrich), respectively. A769662 response curves were normalized to the initial PE contraction. 
Western Blotting 
At the time of euthanasia, the placenta corresponding to the fetus weighing closest to the 
average fetal weight of each dam was flash frozen. Protein extracts were prepared from the 
placental homogenates in Meso Scale lysis buffer (150mM NaCl, 20mM Tris pH 7.5, 1mM 
EDTA, 1mM EGTA, 1% Triton X-100) containing a protease and phosphatase inhibitor cocktail 
(Halt Inhibitor Cocktail 100X, Thermo Fisher Scientific), and the protein concentration was 
determined using the Pierce BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL). 
Proteins (15 µg/lane) were separated by SDS-PAGE on a 4-20% gradient gel and transferred to 
nitrocellulose membranes. Li-Cor protocols were followed for membrane blocking and 
incubations (Li-Cor Biosciences, Lincoln, NE). The membranes were incubated with primary 
antibodies to b-actin, P-AMPK, and AMPK. All primary antibodies were from Cell Signaling 
Technology (Danvers, MA). After subsequent incubation with Li-Cor fluorescent secondary 
antibodies (1:20,000), membranes were imaged and analyzed on a Li-Cor Odyssey CLx. Data 
are presented as fluorescent signal of target protein normalized to b-actin. 
Immunohistochemistry and Immunofluorescence 
Paraffin sections of uterine arteries and placentas were deparaffinized in xylene and 
rehydrated in decreasing concentrations of ethanol (100-80%) and de-ionized water. For antigen 
retrieval, sections were submerged in 10mM, pH 6.0 citrate buffer and boiled in a pressure 
cooker for 30 minutes at 45°C. Sections were blocked in 1% bovine serum albumin (BSA) in 1x 
TBS for 30 minutes. Primary P-AMPK antibody (Cell Signaling Technology) was diluted 1:50 in 
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1% BSA in 1x TBS and applied to sections overnight at 4°C. Secondary anti-HRP antibody 
(Dako, Santa Clara, CA) was applied for 1 hour at room temperature. DAB substrate (Dako) was 
then added and allowed to develop for 5 minutes. Sections were then counterstained with 
hematoxylin for 1 minute, dehydrated with increasing concentrations of ethanol (70-100%) and 
xylene, and then covered with cytoseal and cover slips. 
To localize P-AMPK staining in uterine artery and placental sections, 
immunofluorescence staining was performed for CD31 to identify endothelial cells, and smooth 
muscle actin (SMa) to identify vascular smooth muscle cells in uterine arteries. Placenta was 
categorized by three major functional areas: decidual zone, junctional zone, and labyrinthine 
zone, with the decidual and labyrinthine zones having dense CD31 staining and the junctional 
zone intermediate staining. For immunofluorescence, paraffin sections of uterine arteries and 
placentas were deparaffinized in xylene and rehydrated in decreasing concentrations of ethanol 
(100-80%) and de-ionized water. Antigen retrieval was carried out using a sodium citrate 
solution as described above. Autofluorescence was blocked with 0.8% glycine in PBS at room 
temperature for 30 minutes. Non-specific binding was blocked with overnight incubation with 
10% normal goat serum (NGS) and 10% BSA in PBS, followed by a 1-hour incubation with 
10% NGS and 0.1% saponin in PBS. Primary antibodies were diluted in 10% NGS in PBS and 
incubated at 4°C overnight. Primary antibodies against CD31 and SMa were obtained from Cell 
Signaling Technology (Danvers, MA). Secondary antibodies were applied for 1 hour at room 
temperature, including Alexa Fluor 488 from Invitrogen (Carlsbad, CA), DAPI from Sigma (St. 
Louis, MO), and WGA-FITC from Invitrogen. Sections are sealed with Hard Mount Aqueous 




Ultrasound measures, dam weight, and fetal weight were compared between normoxic 
and hypoxic groups using Student’s unpaired t-test. Contractile response curves to PE as 
measured using myography were expressed as relative to the maximal KCl response in each 
uterine artery. The best-fit line for each PE curve was compared using 2-way analysis of variance 
(ANOVA) with Sidak’s multiple comparisons. The EC50, which represents the concentration of 
drug that gives a half-maximal response, was calculated for each individual curve using 
GraphPad, averaged for a given animal and then expressed as the mean ± SEM for the normoxic 
and hypoxic or other specific treatment groups. The maximum PE response and EC50 were 
compared using Sidak’s multiple comparisons. Response curves to A769662 were expressed as a 
percentage of the initial, 80% maximally PE contraction before vasodilation with increasing 
concentrations of A769662. As above, the best-fit line for each curve was compared using 2-way 
ANOVA with Sidak’s multiple comparisons. Curves were further analyzed by comparing 
maximum % relaxation, EC50, and area under the curve (85) using Sidak’s multiple comparisons. 
Significance was defined as a two-tailed p < 0.05. 
Results 
Reduction of Fetal Weight with Late-Gestation Hypoxia Exposure 
E18.5 fetal weight was reduced in the hypoxia-exposed litters by an average of 34% (Fig. 
II.1A). Maternal food intake, number of pups, and resorptions per litter were similar in the 
normoxic and hypoxic groups (Table II.1), suggesting that the dams tolerated the hyperbaric and 
hypobaric chambers equally well but that clearly fetal growth was reduced. The lesser maternal 
weight gain under conditions of hypoxia (Table II.1) was likely due to the reduction in fetal 
growth as judged by the similarity in maternal weight at E18.5 minus the total weight of the  
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Figure II.1. Effects of Late-Gestation (E14.5-18.5) Hypoxia on Fetal Growth and Uterine 
Artery Blood Flow. A) E18.5 fetal weight was reduced, B) placental weight was increased, and 
therefore C) the ratio of fetal to placental weight was lower indicating a selective reduction in 
fetal growth; n = 10 normoxic, 10 hypoxic dams. D) Uterine artery volumetric blood flow was 
increased with late-gestation hypoxia, and E) uterine index, the ratio of uterine artery blood flow 
to cardiac output, was higher; n = 7 normoxic, 6 hypoxic dams. Data are presented as mean ± 
SEM and analyzed by Student’s unpaired t-test. 
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excised fetuses and placentas (29.3 ± 0.8 vs. 27.8 ± 0.8 g, respectively, p = NS). In contrast to 
the reduction in fetal weight, placental weight was ~7% higher in the hypoxia-exposed group 
(Fig. II.1B), leading to a lower placental efficiency as expressed as the ratio of fetal to placental 
weight (Fig. II.1C). 
Doppler Indices of Uterine Artery Blood Flow and Cardiac Output 
Uterine artery blood flow was increased by 110% in the hypoxic compared to normoxic 
dams (Fig. II.1D). This was due largely to increased uterine artery end-diastolic velocity, which 
resulted in a higher uterine artery mean flow velocity (Table II.1). The hypoxia group’s larger 
(by 67 µm) uterine artery diameter also contributed, although it did not reach significance (Table 
II.1). Heart rate was significantly higher in the hypoxic mice but did not result in greater cardiac 
output (Table II.1). The uterine artery index (i.e., the ratio of uterine artery volumetric blood 
flow to cardiac output) was doubled in hypoxic mice (Fig. II.1E), indicating that a greater 
proportion of total blood flow was directed to the uterus with hypoxia exposure.  
Effects of Hypoxia and Ex Vivo AMPK Activation on Uterine Artery Contractility 
We evaluated the effects of hypoxia on isolated uterine arteries by small-vessel wire 
myography. The contractile response to PE, normalized to the maximum KCl response in each 
vessel, was similar in uterine arteries from normoxic and hypoxic mice whether assessed by 
comparing the whole curve (Fig. II.2A), the maximum PE contractile response, or the EC50 of 
the PE response curves (Fig. II.2E). The maximum contractile response to KCl was also similar 
in the normoxic and hypoxic groups (Fig. II.2E).  
AMPK activation by A769662 blunted sensitivity to PE in uterine arteries from both 








Figure II.2. Uterine Artery Contractility Measured by Wire Myography and the Effect of 
AMPK Activation on Blunting the Contractile Response. A) The contractile response to PE 
was similar in uterine artery from normoxic and hypoxic mice. A769662 blunted the PE response 
in both B) normoxic and C) hypoxic mice. D) The magnitude of A769662 effects on blunting PE 
response were similar in both groups. E) Neither the maximum KCl response nor the maximum 
response to PE were changed by hypoxia or A769662, but sensitivity to PE was reduced by 
A769662 in vessels from both normoxic and hypoxic groups. The contractile response to PE was 
normalized to the maximum potassium chloride response in each vessel studied. Data are 
presented as mean ± SEM and NS = non-significant. Different italicized letters represent 
significant differences using either the overall result using 2-way ANOVA or 2-way ANOVA 
with Sidak’s multiple comparisons. 
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activation thus increased the EC50) in both groups while maximum PE response remained 
unaltered (Fig. II.2E).  
Effect of Hypoxia on Uterine Artery Vasodilation 
In uterine arteries pre-constricted to 80% of their maximal PE response, AMPK 
activation by A769662 resulted in similar dose-dependent vasodilation in the normoxic and 
hypoxic mice (Fig. II.3A). In uterine arteries from normoxic mice, inhibition of nitric oxide 
synthase by L-NAME reduced the maximum vasodilatory effects of AMPK activation by 42%, 
indicating that some but not all AMPK-induced vasodilation was dependent on increased 
endothelial nitric oxide production. The addition of indomethacin to inhibit production of 
cyclooxygenase products did not further decrease the vasodilatory effects of AMPK activation in 
the normoxic animals, indicating that there was little, if any, contribution of vasodilator 
prostaglandins (Fig. II.3B). In hypoxic mice, inhibition of nitric oxide synthase by L-NAME 
blocked the vasodilatory effects of AMPK activation by 29%, and the addition of the 
cyclooxygenase inhibitor indomethacin further blunted the effects of AMPK activation by an 
additional 18%. This indicated that the production of both nitric oxide and vasodilator 
prostaglandins contributed to AMPK activation-induced vasorelaxation in hypoxic mice (Fig. 
3C). In other words, since the effect of L-NAME on blunting AMPK-induced vasodilation was 
significantly greater in normoxic compared to hypoxic mice, the vasodilator role of endothelial 
nitric oxide synthase was greater in the uterine arteries from the normoxic than hypoxic group. 
L-NAME and indomethacin blunted the vasodilatory effects of AMPK activation both by 
reducing the maximum percent relaxation and the overall sensitivity to the effects of AMPK 








Figure II.3. Vasodilatory Effect of AMPK Activation in Pre-Constricted Uterine Artery. A) 
Pre-constricted uterine arteries from normoxic and hypoxic mice similarly vasodilated in 
response to the AMPK activator A769662. B) Incubation with L-NAME reduced the 
vasodilatory effect of A769662 in uterine arteries from normoxic mice and C) did so to a lesser 
degree in hypoxic mice. Addition of indomethacin did not further reduce the effect of A769662 
in normoxic mice but did so in hypoxic mice. D) Comparison of curves by maximum relaxation, 
EC50, and AUC. Data are presented as mean ± SEM and normalized to initial PE contraction. 
Response curves were analyzed by 2-way ANOVA. In part D, the overall ANOVAs are shown, 
and different italicized letters represent results of Sidak’s multiple comparisons. NS = non-
significant.   
 22 
of AMPK activation may be due to endothelium-derived hyperpolarizing factor or smooth 
muscle factors. 
The vasodilatory responses to ACh were similar in uterine arteries from both normoxic 
and hypoxic mice (Fig. II.4A). In normoxic mice, L-NAME significantly blunted ACh 
vasodilation, as analyzed by the maximum % relaxation and the AUC of the ACh response 
curves (Fig. II.4B). However, L-NAME did not significantly blunt ACh vasodilation in hypoxic 
animals indicating that hypoxic exposure blunted the contribution of increased nitric oxide 
production to ACh-stimulated uterine artery vasodilation. 
Less AMPK Activation in Uteroplacental Tissues with Hypoxia 
Immunostaining for P-AMPK in uterine arteries from normoxic mice indicated AMPK 
activation in the endothelial cells, while P-AMPK immunostaining was not present in the uterine 
artery from hypoxic mice (Fig. II.5A). Qualitative assessment of the uterine artery CD31 and 
smooth-muscle actin staining suggested that the normoxic (n=3) compared to hypoxic (n=4) 
mice had more layers of fibro-collagenous tissue within the tunica intima, as there was a 
distinctive layer between the endothelium and smooth muscle layer.  
We also evaluated changes in placental AMPK signaling. P-AMPK protein expression 
was higher in the placenta from normoxic compared to hypoxic dams, while total AMPK protein 
expression levels were unchanged, as measured by western blot of total homogenized placenta 
(Fig. II.5C). When visualized using immunohistochemistry, P-AMPK was localized to the 
junctional zone of the placenta from normoxic mice and not detectable in placenta from hypoxic 







Figure II.4. Vasodilatory Response to ACh in Pre-Constricted Uterine Artery. A) PE pre-
constricted uterine arteries from normoxic and hypoxic mice similarly vasodilate in response to 
ACh. Incubation with L-NAME reduces the vasodilatory effect of ACh in normoxic compared to 
hypoxic mice. B) The EC50 of the ACh response curve is increased in L-NAME treated uterine 
arteries compared to control. The maximum % relaxation is reduced, and AUC is increased with 
L-NAME treatment in normoxic uterine arteries only. N = 6 normoxic mice, 8 hypoxic mice. 
Data are presented as mean ± SEM. Different italicized letters represent statistical differences 






Figure II.5. Characterization of Placental and Uterine Artery AMPK Activation. A) By 
immunohistochemistry, P-AMPK was pronounced in the uterine arterial smooth muscle cells 
from normoxic mice (n=3) but not visible in the uterine artery from hypoxic mice (n=4). In 
normoxic mice, there was a distinctive layer between the vascular smooth muscle cells and 
endothelium (stained in red with wheat germ agglutinin), pointed to by white arrows. B) 
Immunohistochemistry staining for placental P-AMPK revealed high AMPK activation in the 
labyrinthine zone of placentas from normoxic mice but was largely absent from hypoxic 
placentas. C) By western blot, AMPK activation was lower in the total placental homogenate 




This is, to the best of our knowledge, the first report of volumetric uterine artery blood 
flow in a murine, hypoxia-induced model of late gestation fetal growth restriction. We found that 
late-gestation hypoxia reduced fetal weight and increased uterine artery blood flow. Neither of 
these changes were not associated with alterations in uterine artery contractile responses to PE or 
dilator responses to AMPK activation or ACh but were paralleled by lesser AMPK activation in 
uterine arteries or placental tissues. Our observations suggest that while the rise in uterine artery 
blood flow under hypoxic conditions may serve to partially compensate for reduced ambient 
oxygen availability, it is insufficient to prevent fetal growth restriction. 
Consistent with other studies of hypoxic rodent pregnancy (37, 39), we saw a 34% 
reduction in E18.5 fetal weight with late-gestation hypoxia equivalent to 10.5% inspired O2. 
Profound hypoxia is necessary to induce IUGR in small animal models as shown by inspired 
oxygen levels of 12 or 16% (equivalent to 4500 or 2100 m) failing to reduce fetal weight in 
pregnant guinea pigs or mice (86, 87). Conversely, in humans, marked reductions in birth weight 
are seen at such altitudes (17, 88, 89) with grading effects being seen with increasing altitude 
(22). Similar to previous reports, we found a slight increase in placental weight (86, 87) and a 
reduction in placental efficiency, calculated as the ratio of fetal to placental weight, with hypoxia 
(37). Human studies of gestational hypoxia, on the other hand, report inconsistent changes in 
placental weight, with increases (90), decreases (91, 92), or no change (93, 94) reported.  
Based on prior human work demonstrating that HA residence decreases the pregnancy-
associated rise in uterine artery blood flow and correlates with reduced fetal weight (74) and 
uterine artery diameter (75, 95), we expected our murine model of  hypoxia-induced fetal growth 
restriction to show lower uterine artery blood flows. In contrast, volumetric uterine artery blood 
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flow was greater in dams exposed to hypoxia compared to their normoxic counterparts despite a 
34% lower E18.5 fetal weight. Greater uterine artery blood flow among hypoxic dams was not 
due to increased cardiac outputs but was associated with higher end-diastolic velocity and a 
lower pulsatility index, resulting in almost twice as great a proportion of the cardiac output 
flowing through the uterine artery. This is the opposite of what has been seen in high-altitude 
preeclamptic women in whom there was less uterine artery relative to total blood flow than seen 
in normotensive pregnant women (96). Other species-specific differences in vascular responses 
to pregnancy are also likely to exist given that the decreased pulsatility index we observed was 
consistent with a rat model of hypoxia-induced IUGR (97) but unlike a report using guinea pigs 
in which hypoxia-induced fetal growth restriction was accompanied by an increased pulsatility 
index (37). 
In terms of the effects of hypoxia on uterine artery vasoreactivity, like other reports we 
found that neither the contractile response to PE nor the vasodilator response to ACh was 
unaffected (39, 76, 98). However, while hypoxic exposure exaggerated the vasodilator response 
to AMPK in mice exposed to 10% oxygen throughout gestation in a previous study (39), we 
found no such effect suggesting that the duration of hypoxia may influence AMPK-induced 
vasodilation. Consistent with previous experimental animal (76, 97, 99) or human (100) 
observations, we found that AMPK- or ACh-induced vasodilation was less dependent on 
increased NO production, indicating that the greater uterine artery blood flow seen in our 
hypoxic mice was not likely due to upregulation of nitric oxide signaling.  
To determine whether differences in uterine artery structure may have contributed to the 
hypoxia-associated increase in uterine artery blood flow and larger uterine artery diameter 
observed, we qualitatively assessed the number of cell layers in the uterine arteries from the 
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hypoxic and normoxic mice. We noted that there were fewer cell layers in the intimal layer 
surrounding the vessel lumen in hypoxic mice, suggesting less fibro-collagenous cells and 
possibly a more distensible phenotype with hypoxia. Strengthening this possibility, previous 
studies by our group in guinea pigs found that chronically-hypoxic animals had more than twice 
as much uterine artery distensibility or half the stiffness when compared to normoxic pregnant 
animals (101). We speculate that the increased uterine artery blood flow we observed at high 
altitude may be due, in part, to increased uterine artery distensibility and provide a rationale for 
future study on the effects of hypoxia on uterine artery compliance. 
Our study benefited from certain strengths but also had limitations. First, utilizing a 
murine model allowed for tight control of the severity and duration of hypoxia exposure without 
other pregnancy complications. While this late-gestation hypoxia model does not fully mimic the 
human HA condition since the hypoxic exposure was initiated late in pregnancy, our protocol 
has the advantage of enabling having pregnancies for study since, in our experience, hypoxia 
throughout gestation in the murine model frequently results in resorption of the entire litter. 
Additionally, the timing of our late-gestation model more closely resembles hypoxic disorders of 
pregnancy insofar as IUGR and preeclampsia are thought to involve uteroplacental hypoxia 
beginning mid- or late-gestation (102) and therefore may be more clinically relevant. Second, we 
were able to determine uterine artery diameter using B-mode color Doppler, therefore allowing 
for calculation of volumetric uterine artery flow, for which we believe that these were the first 
such measurements in hypoxia-exposed mice. Prior to initiating our study, we carefully 
considered the possibility that color Doppler ultrasound might over-estimate vessel diameter as 
the color appears to “bleed” over the non-color image. However a prior study compared B-mode 
color Doppler measurements of murine uterine artery diameter to those obtained from vessel 
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casts, and concluded that these two methods yielded similar values (103), suggesting that our 
values were not over-estimates. Moreover, even if there were an over-estimation of vessel 
diameter, this would be similar in both normoxic and hypoxic groups and thus would not prevent 
their comparison. Disadvantages of our study, however, was that given the small size of murine 
vessels, we were unable to study vessels downstream of the main uterine artery that are the 
primary sites of uterine vascular resistance. Future studies in humans or larger animal models 
will be beneficial to determine the contribution of downstream vessels to hypoxia-associated 
alterations in uterine artery blood flow. Finally, A technical limitation of both the ultrasound and 
myography measurements was that these measurements were done under normoxia and 
hyperoxia, respectively, rather than keeping the mice or their uterine arteries under study 
conditions; however, this is standard protocol (37, 39, 103). 
One factor that may be contributing to the fetal growth restriction that we observed with 
hypoxia is the inhibition of the mechanistic target of rapamycin (mTOR), thought to be involved 
in regulating fetal growth in response to maternal nutrient and oxygen availability (104). While 
AMPK can downregulate mTOR signaling (105), we did not find elevated AMPK activation but 
rather, found less AMPK activation with hypoxia in both uterine artery and placenta tissues. 
However, mTOR can be downregulated by hypoxia independently of P-AMPK (106, 107), so 
evaluation of mTOR signaling is justified to determine whether upregulation of mTOR may be 
contributing to the hypoxia-associated fetal growth restriction observed. Another factor that may 
be contributing to hypoxia-induced fetal growth restriction is higher placental vascular 
resistance; although uterine artery resistance was reduced with hypoxia, it is possible that 
placental resistance might be greater, so that the higher uterine artery blood flow with hypoxia 
was not actually reaching the fetuses. Consistent with this possibility, we measured lower P-
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AMPK in placentas of hypoxic mice compared to normoxic mice, which could indicate a loss of 
P-AMPK-induced vasodilatory effects in the placenta. 
Overall, our studies demonstrated that despite an increase in uterine artery blood flow, 
fetal weight was reduced by late-gestation hypoxia in mice. There was no change in uterine 
artery vasoreactivity but, based on an apparent reduction in the number of layers of fibro-
collagenous tissue within the uterine artery tunica intima, we speculate that there was greater 
uterine artery compliance with hypoxia. As in a previous study AMPK activation ex vivo 
opposes vasoconstriction (39). While we found here that hypoxia reduced AMPK activation in 
the uterine artery and placental tissues, the uterine arteries remained responsive to ex vivo AMPK 
activation, indicating that these pathways were still functional and could be targeted 
pharmacologically. Ongoing studies will evaluate whether in vivo AMPK modulation affects 
fetal growth in our model of hypoxic murine pregnancy and, if so, whether such effects are 





AMP-ACTIVATED PROTEIN KINASE ACTIVATOR AICAR ATTENUATES 
HYPOXIA-INDUCED FETAL GROWTH RESTRICTION IN MICE BY IMPROVING 
UTERINE ARTERY BLOOD FLOW 
Introduction 
Pregnancies complicated by uteroplacental hypoxia include intrauterine growth 
restriction (IUGR), affecting up to 10% of pregnancies (1); gestational diabetes mellitus, which 
affects up to 9% of all USA pregnancies (2); preeclampsia, affecting up to 8% of pregnancies 
(3); inflammatory diseases during pregnancy (4); high altitude pregnancy; and in overweight or 
obese pregnancy, occurring in at least 45% of pregnancies (5). Despite their prevalence, there is 
almost a complete lack of safe and effective therapies for cases of uteroplacental hypoxia. As 
hypoxia is important in the pathophysiology of many pregnancy complications (41), we are 
interested in evaluating potential therapeutic targets for ameliorating uteroplacental ischemia by 
increasing  oxygen delivery to the developing fetus. 
One such potential therapeutic target for improving uteroplacental blood flow is AMP-
activated protein kinase (AMPK). AMPK is a key metabolic regulator and its activation has 
beneficial metabolic effects in pregnancy (108, 109). It also has vasodilatory effects, 
systemically by lowering blood pressure (61), as well as locally in the uterine artery by raising 
uterine artery blood flow (109, 110). Ex vivo studies provide further evidence that AMPK 
activation is a vasodilator generally (61, 111-113) and specifically in the uterine artery (39, 114). 
Providing an additional mechanism of increased uteroplacental blood flow, AMPK-activating 
drugs have also been shown to have pro-angiogenic effects in the uteroplacental unit (115).  
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The mechanisms of AMPK-activating drugs differ and thus their safety and efficacy vary. 
In humans, the AMPK-activating drug metformin has been safely used during pregnancy for 
decades (116), while there is recent evidence that another such drug sildenafil is ineffectual and 
possibly unsafe (117). A study in non-human primates found that resveratrol, while improving 
maternal metabolism and increasing uterine artery blood flow, resulted in concerning overgrowth 
of the fetal pancreas (109). An AMPK-activating drug that has not been used in human 
pregnancy is 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR), which was the first 
drug identified to activate AMPK and does so directly by its conversion into an AMP mimetic 
called ZMP (118, 119). Here, we use AICAR in a mouse model to begin to evaluate its 
effectiveness in improving uterine artery vasodilation and blood flow in pregnancy complicated 
by hypoxia. 
 We utilized a murine model of late-gestation hypoxia-induced IUGR in order to model 
hypoxia during pregnancy in the absence of overt pathology. Our objective was to determine 
whether in this model pharmacologic AMPK activation by AICAR treatment was sufficient to 
increase uterine artery blood flow and fetal growth in hypoxic mice. We also determined whether 
AMPK activation was necessary for normal uterine artery blood flow and fetal growth in 
normoxic mice by inhibiting AMPK with Compound C. We also assessed whether 
pharmacologic AMPK modulation affects uteroplacental tissues directly.  
Pregnant mice were exposed to normoxia or hypoxia in late gestation and treated with 
vehicle, AICAR, or Compound C. We evaluated the effects of hypoxia and pharmacologic 




Materials and Methods 
Mice, Drug Treatment, and Late-Gestation Hypoxia Exposure 
C57Bl/6 mice were obtained from Charles River (Wilmington, MA). Female mice (20-
25g) were mated with male breeders overnight, with a copulatory plug as evidence of successful 
breeding at embryonic day (E)0.5. On E13.5, a subcutaneous drug pellet (Innovative Research of 
America, Sarasota, FL) was inserted dorsally under 1-2% isoflurane anesthesia. The three 
treatment groups received a 5-day constant-release pellet containing 1) vehicle (VEH), 2) 200 
mg/kg/day of 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR; Toronto Research 
Chemicals, Ontario, Canada), or 3) 20 mg/kg/day dorsomorphin hydrochloride, also known as 
Compound C (ComC; Enzo Life Sciences, Farmingdale, NY). AICAR was chosen as the AMPK 
agonist as its mechanism is known and it is an effective AMPK activator in vivo; namely, 
AICAR is phosphorylated by adenosine kinase and converted into ZMP, an AMP mimetic, thus 
directly activating AMPK. ComC is the only available cell-permeable AMPK inhibitor. 
Beginning at E14.5, pregnant mice were housed in hyperbaric (PB ~ 760 mmHg) or 
hypobaric (PB ~ 385 mmHg) chambers to simulate normoxia or hypoxia, respectively, until 
euthanasia by carbon dioxide asphyxiation and cervical dislocation at E18.5. Uterine arteries 
were excised for wire myography studies. Fetuses and placentas were excised and weighed. All 
animal procedures and protocols were completed in accordance with NIH Guide for the Care and 
Use of Laboratory Animals (84) and were approved by the Institutional Animal Care and Use 






Doppler ultrasounds were performed in the Cardiovascular Pre-Clinical Core at the 
University of Colorado-Denver Anschutz Medical Campus (1611 m) on E17.5 pregnant mice 
while breathing room air and under 1-2% isoflurane anesthesia using a 30-MHz pulsed Doppler 
system (Vevo 2100, Visual Sonics, Toronto, ON). Aortic stroke volume and heart rate were 
measured to calculate cardiac output (stroke volume in µl/min x heart rate in bpm). The uterine 
artery was identified at the point where it appears to cross over the external iliac artery. Uterine 
artery peak systolic velocity, end diastolic velocity, and mean velocity were determined by 
manually tracing and then averaging the values obtained from waveform tracings of good quality 
from three consecutive cardiac cycles. Uterine artery pulsatility index (PI) was calculated as 
(systolic–diastolic velocity)/systolic velocity. Uterine artery diameter was approximated using B-
mode color Doppler. While B-mode color may have exaggerated the actual dimension, such an 
effect was considered uniform across animals and thus enabled comparisons of uterine artery 
volumetric blood flow, calculated as p x uterine artery radius2 x uterine artery mean velocity. 
One uterine artery was chosen at random for study so volumetric uterine artery blood flow was 
multiplied by two to approximate the total uterine artery blood flow. The uterine artery index 
was calculated as total uterine artery blood flow/cardiac output to determine the portion of 
cardiac output was flowing through the uterine arteries.  
Small-Vessel Wire Myography 
Immediately following euthanasia, one or both main uterine arteries were isolated in ice-
cold PBS, cleaned of connective tissue, and cut into 2 mm segments. Segments were mounted 
using 2 stainless steel 40 µm wires for each chamber of a 4-channel, small vessel wire myograph 
(Danish Myo Technology 610M, Aarhus, Denmark). The mounted vessels were continuously 
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maintained at 37°C and oxygenated (95% O2/5% CO2; Airgas, Radnor, PA) while submerged in 
Krebs solution (118.5mM NaCl, from Sigma Aldrich, St. Louis, MO; 25mM NaHCO3, 4.75mM 
KCl, 1.2mM MgSO47H20, 1.2mM KH2PO4, 2.5mM CaCl2, 11.1mM D-Glucose, all from Thermo 
Fisher Scientific, Waltham, MA). After a 30-minute equilibration, the vessels were normalized to 
an internal diameter of 0.9 of L13.3kPa, and this diameter was maintained for the rest of the 
protocol. Vessels were then equilibrated for another 30 minutes before vasoreactivity studies 
began. 
Viability was demonstrated by contractile responses of at least 2 mN to 60 mM potassium 
chloride (KCl) and 10 µM phenylephrine (PE; Sigma-Aldrich), and intact endothelium was 
demonstrated in pre-constricted vessels by an 80% or greater vasodilator response to 1 µM 
acetylcholine (ACh; Acros Organics, Pittsburgh, PA). The full contractile response to PE was 
determined across a 1 nM-100 µM range and repeated after incubation with the AMPK agonist 
A769662 (30 µM; Tocris Bioscience, Bristol, UK) to determine the effects of AMPK activation 
on PE contraction. PE response curves were normalized to the maximum KCl response to control 
for the length of each uterine artery segment being studied.  
Statistical Analysis 
The effects of hypoxia and drug treatment on feto-placental weights and ultrasound 
measures were determined using 2-way ANOVA with differences between groups identified 
using Sidak’s multiple comparisons. Contractile response curves to PE as measured using 
myography were expressed as relative to the maximal KCl response in each uterine artery. The 
best-fit line for each PE curve was compared using 2-way analysis of variance (ANOVA) with 
Sidak’s multiple comparisons. The EC50, which represents the concentration of drug that gives a 
half-maximal response, was calculated for each individual curve using GraphPad, averaged for a 
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given animal and then expressed as the mean ± SEM for the specific treatment groups. The 
maximum PE response, EC50, and AUC were compared using 2-way ANOVA with Sidak’s 
multiple comparisons. Significance was defined as a two-tailed p < 0.05.  
Results 
AMPK Activation Partially Prevents Hypoxia-Induced Fetal Growth Restriction 
 In VEH mice, hypoxia reduced E18.5 fetal weight by 35% (Fig. III.1A, p < 0.001). 
AICAR treatment in hypoxic mice prevented more than half of the fetal growth reduction (p < 
0.05), with hypoxic + AICAR mice only 16% smaller than normoxic + VEH mice. AICAR 
treatment had no effect on fetal weight in normoxic mice. ComC treatment had no effect on fetal 
weight in normoxic or hypoxic mice. Placental weight was slightly increased with hypoxia 
compared to normoxic + VEH mice (Fig. III.1B, p < 0.05), which was prevented in hypoxic + 
AICAR mice (p < 0.05 compared to hypoxic + VEH). In normoxic mice, ComC increased 
placental weight (p < 0.05) but AICAR had no effect. In hypoxic mice, AICAR lowered 
placental weight (p < 0.05) and ComC had no effect. Together, these changes resulted in reduced 
placental efficiency, as calculated by the ratio of fetal to placental weights, with hypoxia 
compared to normoxia in VEH mice (Fig. III.1C, p < 0.001). AICAR treatment in hypoxic mice 
improved placental efficiency compared to VEH (p < 0.05). 
Elevated Uterine Artery Blood Flow is Partly Responsible for Rescue of Fetal Growth with 
AMPK Activation 
 Uterine artery hemodynamics and diameter were measured using Doppler ultrasound. In 
VEH mice, hypoxia reduced the uterine artery resistance and pulsatility indices (Table III.1 p 
<0.001). There was no significant effect of hypoxia on uterine artery diameter (Fig. III.2A), 
mean velocity (Fig. III.2B), or blood flow (Fig. III.2D). 
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Figure III.1. Effect of Hypoxia and Drug Treatment on E18.5 Fetal and Placental Weights. 
A) Hypoxia blunted fetal growth, which was partially prevented by AICAR. B) Hypoxia 
increased placental weight. In normoxic mice, Compound C increased placental weights. In 
hypoxic mice, AICAR reduced placental weights. C) Placental efficiency calculated as ratio of 
fetal to placental weights was reduced by hypoxia and increased in hypoxic mice by AICAR 
treatment. Data were analyzed by two-way ANOVA, shown below each graph. Individual 
groups were compared by Sidak’s multiple comparisons, shown with asterisks on the graphs. N 
= 10 VEH, 9 AICAR, 9 ComC normoxic dams; 10 VEH, 5 AICAR, 5 ComC hypoxic dams. 
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 In normoxic mice, ComC reduced uterine artery diameter compared to normoxic + VEH 
mice (Fig. III.2A, p < 0.01). By ANOVA there was an overall effect of ComC in increasing 
uterine artery mean velocity (Fig. III.2B, p < 0.05), but there was no effect of ComC on uterine 
artery volumetric flow. There was no effect of AICAR in normoxic mice on uterine artery 
diameter or flow measurements. 
 In hypoxic mice, ComC did not change uterine artery diameter or hemodynamics 
compared to hypoxic + VEH. However, AICAR treatment in hypoxic mice had marked affects in 
increasing uterine artery diameter (Fig. III.2A, p < 0.05) and mean velocity (Fig. III.2B, p < 
0.01), thereby increasing uterine artery volumetric flow (Fig. III.2D, p < 0.0001). These changes 
were associated with an increase in both peak systolic and end diastolic velocities (Table III.1).  
 Uterine artery index was calculated as the ratio of uterine artery volumetric blood flow to 
cardiac output, to represent the proportion of total blood flowing through the uterine artery. 
Uterine artery index was similar in all groups but was robustly increased in hypoxic + AICAR 
mice compared to hypoxic + VEH mice (Fig. III.2C), indicating that AICAR selectively 
increased blood flow in the uterine circulation. 
 Cardiac hemodynamics were also determined by Doppler ultrasound. Heart rate was 
elevated in hypoxic compared to normoxic mice, regardless of drug treatment (Table III.1, p < 
0.01), but there was no change in stroke volume or cardiac output with hypoxia or drug 
treatment. 
AMPK Inhibition Increases Uterine Artery Contractility in Normoxic Mice 
 Uterine artery vasoreactivity was studied using wire myography. Neither hypoxia nor 
drug treatment altered the contractile response to KCl. Phenylephrine induced concentration-
dependent vasoconstriction in uterine arteries from VEH (Fig. III.3A), AICAR (Fig. III.3B),  
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Figure III.2. Effect of Hypoxia and Drug Treatment on Uterine Artery Blood Flow. A) 
Uterine artery diameter was reduced by Compound C in normoxic mice and increased by 
AICAR in hypoxic mice. B) Uterine artery mean velocity was elevated with AICAR in hypoxic 
mice. C) UtA index-the ratio of uterine artery blood flow to cardiac output-was higher with 
AICAR in hypoxia mice. D) Blood flow was elevated by AICAR in hypoxic mice. Data were 
analyzed by two-way ANOVA, shown below each graph. Individual groups were compared by 
Sidak’s multiple comparisons, shown with asterisks on the graphs. N = 8 VEH, 5 AICAR, 6 
ComC normoxic dams; 6 VEH, 6 AICAR, 5 ComC hypoxic dams.  
 40 
and ComC (Fig. III.3C) mice exposed to normoxia and hypoxia, with similar responses in all 
groups as analyzed by EC50 and AUC (Table III.2). In normoxic mice, ComC increased the 
maximal response to phenylephrine compared to VEH (Fig. III.3D, p < 0.05); the maximal 
response was unchanged in all other groups. 
 The uterine arteries were incubated with A769662, an AMPK agonist, and phenylephrine 
response curves were repeated. AMPK activation was sufficient to blunt the phenylephrine 
response in all groups; the % decrease in AUC by A769662 was similar in all groups (Table 
III.2). 
Discussion 
Pharmacologic AMPK activation by AICAR was sufficient to partially prevent hypoxia-induced 
fetal growth restriction in mice, in part by improving volumetric uterine artery blood flow due to 
increased vessel diameter and mean velocity. The proportion of cardiac output flowing through 
the uterine artery was markedly higher in hypoxic mice treated with AICAR compared to all 
other groups, indicating that in hypoxic pregnancy, AICAR selectively upregulated uterine artery 
flow. Consistent with these data, pharmacologic AMPK inhibition by ComC reduced uterine 
artery diameter in normoxic mice, providing evidence that physiological levels of AMPK 
activation are necessary for vasodilation in health pregnancy. Together, these findings suggest 
that AMPK is an effective therapeutic target in our model of late-gestation hypoxia-induced fetal 
growth restriction in mice. 
Hypoxia reduced fetal weight by one third, consistent with other studies of hypoxic 
pregnancy in rodent models (37, 39, 120). Similar to previous reports, we found a slight increase 
in placental weight (86, 87) and a reduction in placental efficiency, calculated as the ratio of fetal 




Figure III.3. Effect of AICAR and Compound C on Uterine Artery Vasocontraction. A) PE 
response curves are similar in normoxic and hypoxic mice, and are blunted to a similar extent by 
A769662, in mice treated with VEH B) and with AICAR. C) Compound C treatment enhances 
the PE response in normoxic mice but not hypoxic mice; PE response is blunted by A769662 in 
normoxic and hypoxic mice treated with Compound C. D) Maximum PE contraction is increased 
by Compound C in normoxic mice. In parts A-C, * denotes P < 0.05 in CON vs +A769662 
curves in both Norm and Hx groups. N = 14 Norm, 12 Hx VEH; 7 Norm, 12 Hx AICAR; 13 
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these effects; fetal growth restriction was partially reversed, placental weight augmentation was 
reversed, and reduction in placental efficiency was partially reversed. ComC had no effect on 
fetal weights or placental efficiency, although it did slightly increase placental weight.  
 We measured no effect of drug treatment on cardiac function, as heart rate, stroke 
volume, and cardiac output were unchanged. Heart rate was elevated with hypoxia regardless of 
drug treatment, but not significantly enough that hypoxia affected cardiac output. In the uterine 
artery, despite increased blood flow with AICAR treatment in hypoxic mice, there was no effect 
of drug treatment on uterine artery resistance and pulsatility indices. Rather, these indices were 
consistently lower in hypoxic compared to normoxic mice. The effect of AICAR in hypoxic 
mice of increasing the proportion of cardiac output flowing through the uterine artery was 
therefore not due to increased cardiac output or reduced downstream resistance, but instead was 
due to increased uterine artery diameter, and peak-systolic and end-diastolic velocities. The 
effect of AICAR in selectively increasing uterine blood flow is an exciting result, as recent 
attempts to improve uteroplacental perfusion with sildenafil were unsuccessful due to 
systemically increased blood flow (117). The selective upregulating of uterine flow in pregnancy 
is also important because in human vascular disorders of pregnancy such as preeclampsia 
involve less uterine artery relative to total blood flow than seen in normotensive pregnant women 
(87), indicating that this physiological response needs to be targeted. 
 Consistent with previous reports, hypoxia had no effect on the uterine artery contractile 
response to phenylephrine (39, 76, 98, 121) and AMPK activation with A769662 consistently 
blunted the phenylephrine response (39). In vivo AICAR treatment in normoxic and hypoxic 
mice had no effect on the response to phenylephrine or the ability of the AMPK agonist 
A769662 to blunt the phenylephrine response. In vivo ComC treatment had no effect in hypoxic 
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mice, but in normoxic mice, the maximal phenylephrine response was augmented by 22%. This 
is consistent with the reduced uterine artery diameter we measure in vivo using Doppler 
ultrasound and implicates higher adrenergic signaling in the uterine arteries of mice treated with 
an AMPK antagonist. 
We saw inconsistent effects of the drugs AICAR and ComC in normoxic vs hypoxic 
mice, as AICAR only affected hypoxic mice, and ComC only affected normoxic mice. Prior 
reports have observed a similar phenomenon with activation of AMPK effective only in hypoxic 
conditions. Namely, AICAR treatment in the reduced uterine perfusion pressure (RUPP) model 
in rats restored angiogenic balance but had no effect in control pregnant rats with normal 
uteroplacental perfusion (122). Also, adenosine administration benefitted placental explants 
cultured under hypoxia but not normoxia (123). We suggest that reduction of AMPK activation 
in the placenta with hypoxia, which we have previously reported (114), may be indicative of a 
loss of AMPK activation in uteroplacental tissues, which would allow for more potent 
pharmacologic activation of AMPK compared to a system with AMPK activation present 
already. Conversely, effectiveness of ComC in reducing uterine artery diameter in normoxic 
mice but not hypoxic mice may be due to a normal level of its target, P-AMPK, in normoxic 
uterine arteries but a lack of P-AMPK in hypoxic uterine arteries. 
 Our findings suggest that AICAR is likely acting to prevent hypoxia-induced fetal growth 
restriction by improving uterine artery blood flow, but we also considered other explanations 
which require further investigation. Namely, AMPK is well characterized in its role as a 
metabolic regulator and might be affecting maternal metabolism. However, in a previous report 
of hypoxia-induced fetal growth restriction, hypoxia increased insulin sensitivity in late 
gestation, which the authors concluded contributed to reduced fetal growth, as the dam’s 
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increased glucose uptake prevented sufficient glucose transfer to the fetus  (36). There may be a 
different effect on the dams’ metabolism in our study, however, as the prior report involved a 
lesser hypoxia insult throughout all of gestation, while here we use a late-gestation, greater 
hypoxia insult. Another explanation for AICAR’s prevention of IUGR may be due to increased 
placental perfusion, which could occur by reduction of oxidative stress, as AMPK increases 
antioxidant pathways (124) and reduction of oxidative stress in late gestation improves placental 
perfusion (125).  
 Further experiments are needed to determine the safety of AICAR treatment and its 
specific effects on the fetus. Ongoing studies will evaluate the effects of drug treatment on 
AMPK activation in fetal tissues, particularly fetal liver, to determine whether AICAR and 
ComC are having effects directly on the fetus. As a preliminary test of safety, the litter size was 
unchanged by drug treatment in this study, so treatment with AICAR or ComC did not induce 
late-gestation resorption. 
Further investigation is needed into placental effects of the drug treatment, as placental 
weight was increased in normoxic mice by ComC and markedly decreased in hypoxic mice by 
AICAR, and fetal growth restriction was not fully prevented by AICAR treatment despite a large 
increase in uterine artery blood flow. One concern with pharmacologic AMPK activation in the 
placenta is a subsequent downregulation of mechanistic target of rapamycin (mTOR), as P-
AMPK lessens mTOR complex 1 activity (105). As mTOR complex 1 is important in the 
placenta for fetal growth by regulating nutrient delivery to the fetus (104), downregulation of 
mTOR could contribute to reduced fetal growth, thereby stunting fetal weight rather than 
rescuing it. Ongoing studies will determine whether AICAR treatment is indeed downregulating 
placental mTOR activity. 
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 This first study on the ability of pharmacologic AMPK activation to prevent hypoxia-
induced fetal growth restriction provides compelling evidence to suggest that AMPK is a 
potential target for improving fetal growth in hypoxic pregnancy. These findings together with 
the clinical availability of drugs which activate AMPK provide rationale for continued 
investigation into the mechanisms of AICAR treatment and the safety and efficacy of such drugs 




PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA BLUNTS 
ENDOTHELIN-1-MEDIATED UTERINE ARTERY VASOCONSTRICTION IN A 
MURINE MODEL OF HIGH-ALTITUDE PREGNANCY 
Introduction 
Complications of pregnancy such as intrauterine growth restriction (IUGR) and 
preeclampsia represent an important public health problem (126), as they increase the incidence 
of morbidity for the mother and the offspring during prenatal, postnatal, childhood, and adult 
periods (23, 127-131) but lack effective therapies. Residence at high altitude (HA, > 2500 m) 
during pregnancy is a risk factor for complicated pregnancy, as it results in maternal hypoxia, 
reduced birth weight, and a 3-fold increased incidence of IUGR and preeclampsia (17, 18, 132). 
Studies of human HA pregnancy and animal models of hypoxic pregnancy allow for isolation of 
the effects of hypoxia on uteroplacental blood flow and fetal growth in the absence of other 
pathological changes present in IUGR and preeclampsia. Here, we used an experimental murine 
model of hypoxia-induced IUGR to evaluate the mechanisms by which PPARg activation may 
prevent hypoxia-induced IUGR, focusing on vascular effects of PPARg activation. 
Pregnancy initiates extensive maternal vascular responses that collectively result in 
adequate uteroplacental perfusion in order to support fetal development. Extensive remodeling of 
the uterine spiral arteries, together with alterations in the vasoreactivity and distensibility of 
upstream vessels, including the bilateral uterine arteries, reduce uteroplacental vascular 
resistance and permit a >10-fold rise in blood flow across gestation. Such effects are due, in part, 
to changes in the production of and/or sensitivity to vasodilators (e.g., nitric oxide (NO)) and 
vasoconstrictors (e.g. endothelin 1 (ET-1)) (133). In humans, hypoxia reduces the normal 
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pregnancy-associated rise in uteroplacental blood flow, which is directly correlated to IUGR (74, 
95, 96, 134).  Experimental animal studies indicate that hypoxia exaggerates myogenic tone, 
diminishes uterine artery eccentric growth, and reduces NO-induced uterine artery vasodilation 
(76, 77, 135). 
Here we evaluated vascular effects of PPARg, a ligand-activated transcription factor of 
the nuclear hormone receptor superfamily that governs gene expression by forming a 
heterodimeric complex with the retinoid X receptor (RXR) at the regulatory region of target 
genes. While PPARg is predominantly recognized for its role in the regulation of metabolic 
homeostasis (62), PPARg is also crucial for establishing the uteroplacental villous circulation 
(63, 64) and maintaining maternal vascular function in pregnancy (136-138). Consistent with 
these functions, PPARg is abundantly expressed in the labyrinthine zone of the rodent placenta 
(70), as well as human trophoblast cells (63, 139) and human vascular smooth muscle cells (140, 
141).  
PPARg also exerts potent vasodilatory effects, lowering blood pressure in hypertensive 
disease and improving endothelium-dependent vasodilation (142). Activation of the PPARg 
pathway suppresses synthesis of the vasoconstrictor endothelin-1 (ET-1) and reduces preproET-1 
expression in human vascular endothelial cells (66, 67). PPARg ligands also increase nitric oxide 
(NO) production via PPARg-dependent mechanisms (68). Specifically, PPARg promotes the 
interaction of heat shock protein 90 and endothelial NO synthase (eNOS) and increases 
eNOSser1177 phosphorylation (69). Evidence further indicates that PPARg regulates myogenic 
tone of the mesenteric artery via regulator of G protein signaling 5 (Rgs5)-mediated control of 
protein kinase C and BKCa channel activity (143).  
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Downregulated PPARg expression or activation have been associated with pathogenesis 
of IUGR and preeclampsia (144-147). Our prior human study found reduced PPARg pathway 
gene expression in maternal peripheral blood cells with hypoxia, correlating with smaller birth 
weight (32). In rats, antagonizing PPARg decreased fetal growth in rats (136, 138). Conversely, 
in mice, pharmacologic activation of PPARg with pioglitazone prevented hypoxia-induced fetal 
growth restriction (120). The importance of PPARg activation in pregnancy is likely dependent 
on its vasodilatory effects, demonstrated by experimental animal studies. For instance, treatment 
with the PPARg agonist troglitazone (TGZ) abolished hypertensive responses to angiotensin II 
infusion during pregnancy and normalized fetal growth in a genetic mouse model (Rgs5 +/-) 
otherwise known to be susceptible to hypertension and IUGR (148). 
 In these experiments, we exposed mice to either hypobaric hypoxia or hyperbaric 
normoxia in late gestation and isolated the main uterine artery for vasoreactivity studies using a 
wire myograph. We aimed to determine whether PPARg activation was sufficient to vasodilate 
uterine arteries from normoxic and hypoxic mice, and whether hypoxia-induced IUGR correlated 
with increased endothelin-1 signaling in the uterine artery and/or placenta. 
Methods 
Mice and Late-Gestation Hypoxia Exposure 
 C57Bl/6 mice from Charles River (Wilmington, MA) were mated when female mice 
were 20-25g, and a copulatory plug was evidence of successful breeding at embryonic day 
(E)0.5. At E14.5, pregnant mice were placed in hyperbaric (PB ~ 760 mmHg) or hypobaric (PB ~ 
385 mmHg) chambers to simulate normoxia or hypoxia, respectively, until euthanasia by carbon 
dioxide asphyxiation and cervical dislocation at E18.5. The main uterine arteries were excised 
and cleaned of surrounding connective tissue for immediate use in wire myography. Fetuses and 
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placentas were excised, cleaned of fetal membranes, and weighed, and placentas were 1) fixed in 
4% paraformaldehyde overnight then embedded in paraffin or 2) flash frozen in liquid nitrogen 
for homogenization and protein extraction. All animal procedures and protocols were completed 
in accordance with NIH Guide for the Care and Use of Laboratory Animals (84) and were 
approved by the Institutional Animal Care and Use Committee at the University of Colorado. 
Small-Vessel Wire Myography 
 The main uterine arteries from dams at E18.5 were cleaned from surrounding connective 
tissue and stored in ice-cold PBS. Vessel segments 2 mm long were mounted on two 40 µm 
wires in a four-chamber, small-vessel wire myograph (DMT 610, Copenhagen, Denmark) in 
37°C Krebs solution (118 mmol/L NaCl, 4.7mmol/L KCl, 1.2 mmol/L MgSO4, 1.2 mmol/L 
KH2PO4, 25 mmol/L NaHCO3, 11 mmol/L glucose, 2.5 mmol/L CaCl2), bubbling with 95% O2, 
5% CO2. Vessels were equilibrated for 20 minutes, normalized to a resting tension equivalent to 
13.3 kPa, then equilibrated for 20 additional minutes. A “wake-up protocol” was followed in 
which vessels were constricted with sub-maximal (60 mmol/L) and maximal (120 mmol/L) 
concentrations of KCl, then a sub-maximal concentration of phenylephrine (10 µmol/L) followed 
by acetylcholine (1 µmol/L) to test for an intact endothelium. Phenylephrine (10 µmol/L) pre-
constricted vessels were exposed to TGZ (1-100 µmol/L) with and without pre-incubation with 
L-NAME (10 µmol/L) to determine the contribution of NO production to effects of TGZ. The 
contractile response to ET-1 was determined (0.1-10 nmol/L) and repeated after incubation with 
the PPARg agonist TGZ (1 µmol/L). 
Placental Immunohistochemistry  
Placentas from dams at E18.5 were cleaned of fetal membranes, fixed overnight in 4% 
paraformaldehyde, and embedded in paraffin. Paraffin sections were deparaffinized in xylene 
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and rehydrated in decreasing concentrations of ethanol (100-80%) and de-ionized water. For 
antigen retrieval, sections were submerged in 10mM, pH 6.0 citrate buffer and boiled in a 
pressure cooker for 30 minutes at 45°C. Sections were blocked in 1% bovine serum albumin 
(BSA) in 1x TBS for 30 minutes. Primary antibodies against ET-1 receptor A, and ET-1 receptor 
B (Thermo Fisher Scientific, Rockford, IL) were diluted 1:1000 in 1% BSA in 1x TBS and 
applied to sections overnight at 4°C. Secondary anti-HRP antibody (Dako, Santa Clara, CA) was 
applied for 1 hour at room temperature. DAB substrate (Dako) was then added and allowed to 
develop for 6 minutes. Sections were then counterstained with hematoxylin for 1 minute, 
dehydrated with increasing concentrations of ethanol (70-100%) and xylene, and then covered 
with cytoseal and cover slips. 
Placental Western Blots 
Placentas from dams at E18.5 were cleaned of fetal membranes and flash frozen. 
Placentas were homogenized using a sonicator in Meso Scale lysis buffer (150mmol/L NaCl, 
20mmol/L Tris pH 7.5, 1mmol/L EDTA, 1mmol/L EGTA, 1% Triton X-100) containing a 
protease and phosphatase inhibitor cocktail (Halt Inhibitor Cocktail 100X, Thermo Fisher 
Scientific). The protein concentration was determined using the Pierce BCA Protein Assay Kit 
(Pierce Biotechnology, Rockford, IL). Proteins (15 µg/lane) were separated by SDS-PAGE on a 
4-20% gradient gel and transferred to nitrocellulose membranes. Li-Cor TBS Blocking Buffer 
was used for membrane blocking and antibody incubations (Li-Cor Biosciences, Lincoln, NE). 
The membranes were incubated with primary antibodies to b-actin (Cell Signaling Technology, 
Danvers, MA), ET-1 receptor A, and ET-1 receptor B (Thermo Fisher Scientific). After 
subsequent incubation with Li-Cor fluorescent secondary antibodies (1:20,000), membranes 
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were imaged and analyzed on a Li-Cor Odyssey CLx. Data are presented as fluorescent signal of 
target protein normalized to b-actin. 
Statistical Analysis 
Fetal and placental weights and their ratio were compared between normoxic and hypoxic 
groups using Student’s unpaired t-test. Response curves to TGZ were expressed as the percent 
relaxation after an initial, 80% maximal PE contraction. The best-fit line for each curve was 
compared using 2-way ANOVA with Sidak’s multiple comparisons. Curves were further 
analyzed by comparing maximum % relaxation, AUC, and EC50 using Sidak’s multiple 
comparisons. Significance was defined as a two-tailed p < 0.05. The contractile response curves 
to ET-1 measured by wire myography were expressed as a fraction of the maximal KCl response 
in each uterine artery. The best-fit line for each ET-1 curve was compared using 2-way ANOVA 
with Sidak’s multiple comparisons. The area under the curve (85), representing the overall 
sensitivity of the uterine arteries to ET-1, and the EC50, representing the concentration of drug 
that gives a half-maximal response, were calculated for each individual curve using GraphPad, 
averaged for a given animal and then expressed as the mean ± SEM for the normoxic and 
hypoxic or other specific treatment groups. The maximum ET-1 response, AUC, and EC50 were 
compared using Sidak’s multiple comparisons.  
Results 
Late-Gestation Hypoxia Reduced Fetal Growth and Placental Efficiency 
Hypoxia exposure from gestational day (149) 14.5 to 18.5 reduced GD18.5 fetal weight 
by 38% (Fig. IV.1A; p < 0.0001). Placental weights trended higher (Fig. IV.1B; p = 0.08) in 
hypoxic compared to normoxic dams. Placental efficiency, as calculated by the ratio of fetal to 





Figure IV.1. Effects of Late-Gestation Hypoxia on E18.5 Feto-placental Weights. Hypoxia 
resulted in A) smaller fetal weights, B) similar placental weights, and C) reduced placental 
efficiency (ratio of fetal to placental weights) compared to normoxic dams. Data are presented as 
means ± SEM and compared by Student’s t-test; n = 8 normoxic dams, 8 hypoxic dams. 
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utilizing the same model of hypoxia-induced fetal growth restriction reported that there was no 
effect of hypoxia on litter size, maternal food intake, or resorption number, indicating that dams 
likely tolerated the normoxic and hypoxic chambers equally well and fetal growth restriction was 
not due to maternal stress. 
Pharmacologic PPARg Activation Vasodilated Uterine Arteries 
 PPARg activation with TGZ resulted in vasodilation of uterine arteries from both 
normoxic and hypoxic mice (Fig. IV.2A). The uterine arteries from normoxic and hypoxic mice 
had a similar maximum vasodilator response to TGZ (Fig. IV.2B), although the overall 
sensitivity to TGZ was higher in the hypoxic group (Fig. IV.2C; 2-way ANOVA for Hx effect, p 
< 0.05), without a significant effect on the EC50 (12.1 ± 2.0 vs 2.9 ± 0.9 µmol/L, NS). Inhibition 
of nitric oxide synthase by L-NAME raised the EC50 in both normoxic and hypoxic groups (34.3 
± 13.1 vs 37.8 ± 18.9 µmol/L respectively; p < 0.05 compared to controls), indicating that nitric 
oxide production contributed to the vasodilatory effects of TGZ in both groups. L-NAME 
blunted the maximum vasodilator response to TGZ by 33% in normoxic mice (Fig. IV.2B; p < 
0.05) but did not blunt the maximum vasodilator response to TGZ in hypoxic mice. These 
findings indicate a lesser contribution of nitric oxide to the effects of TGZ in hypoxic mice, 
indicating that nitric oxide production may be reduced by hypoxia. 
Uterine Artery Endothelin Signaling was Upregulated by Hypoxia 
 The uterine arteries from normoxic and hypoxic mice contracted in response to ET-1 
(Fig. IV.3A). The maximum contractile response to ET-1 was augmented by hypoxia (Fig. 
IV.3B; p < 0.05), and the overall sensitivity remained the same (Fig. IV.3C), as did the EC50 




Figure IV.2. Effects of In Vivo Hypoxia and Ex Vivo L-NAME Incubation on Uterine 
Artery Troglitazone-Induced Vasodilation. A) Concentration response curves to troglitazone 
(TGZ; 0.1-100 µM) with or without pre-incubation with L-NAME (30 min; 10 µM) in uterine 
arteries from normoxic or hypoxic mice. B) The maximum vasodilator response to TGZ was 
blunted by L-NAME in normoxic dams. C) Overall sensitivity to TGZ as represented by area 
under the curve. Data are presented as means ± SEM and compared by 2-way ANOVA with 
differences between groups identified by Sidak’s multiple comparisons; n = 10 NORM, 10 







Figure IV.3. Effects of In Vivo Hypoxia and Ex Vivo Troglitazone on the Uterine Artery 
Contractile Response to Endothlelin-1. A) Concentration response curves to endothelin-1 (ET-
1; 0.1-30 nM) with or without 30 min pre-incubation with troglitazone (TGZ; 10 µM) in uterine 
arteries from normoxic or hypoxic mice. B) Maximum contractile response to ET-1 was higher 
in hypoxic dams, and TGZ blunted the maximal response in both normoxic and hypoxic dams. 
C) Overall sensitivity to ET-1 as represented by area under the curve. Data are presented as 
means ± SEM and compared by 2-way ANOVA with differences between groups identified by 
Sidak’s multiple comparisons; n = 11 NORM, 11 NORM + TGZ, 15 HX, 14 HX + TGZ. 
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with ET-1 blunted the maximum response to ET-1 in both normoxic and hypoxic groups (Fig. 
IV.3B; p < 0.05 or p < 0.0001 respectively); the hypoxic ET-1 response after TGZ incubation 
was blunted to less than the normoxic response. The overall sensitivity to ET-1 was reduced by 
TGZ in both the normoxic and hypoxic groups (Fig. IV.3C; 2-way ANOVA for TGZ effect, p < 
0.05), and the EC50 was reduced by TGZ in both normoxic and hypoxic groups (13.7 ± 13.6 
µmol/L and 2.55 ± 2.54 mmol/L respectively; p < 0.05 compared to controls). The contractile 
response to potassium chloride was similar in normoxic and hypoxic mice (6.36 ± 0.48 vs 6.13 ± 
0.38 mN respectively, NS), indicating that the mechanical integrity of the uterine arteries was not 
affected by hypoxia. 
Placental Endothelin Receptors were Upregulated by Hypoxia 
 Endothelin signaling in the placenta is important for regulating placental perfusion and 
nutrient delivery to the fetus such that increased endothelin signaling is associated with 
pregnancies complicated by reduced blood flow to the fetus (95, 150). Endothelin receptors A 
and B were present in placentas from normoxic mice in the junctional zone (Fig. IV.4A, B). 
Both receptors were upregulated in placentas from hypoxic mice, with greater expression in the 
junctional zone and expression in the labyrinthine zone (Fig. IV.4C, D). 
Discussion 
The PPARg pathway plays a vital role for several processes required for successful 
pregnancy and has been implicated for the development of IUGR and preeclampsia. In this first 
report to explore effects of hypoxia on PPARg-induced vasodilation, we found that 
pharmacologic PPARg activation vasodilates murine uterine arteries and is more potent in 




Figure IV.4. Effects of In Vivo Hypoxia on Expression and Localization of ET-1 Receptors 
in the Placenta. Immunohistochemical staining in representative placentas from A, B) normoxic 
and C, D) hypoxic mice reveal higher expression of both ET-1 receptors A and B with hypoxia. 
n = 3 normoxic, 3 hypoxic dams for each receptor. 
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downregulating production of the potent vasoconstrictor ET-1, we hypothesized that 
pharmacologic activation of PPARg would partially act by decreasing ET-1 signaling. In support 
of this, PPARg activation markedly blunted the ET-1 vasoconstrictor response. Our findings 
further indicate that ET-1 signaling is upregulated by hypoxia in both the uterine artery and 
placenta, since uterine artery contractile response and expression of placental endothelin-1 
receptors were elevated. We suggest that increased ET-1 signaling is partly responsible for 
reduced fetal growth with hypoxia. Together, our findings suggest that upregulated ET-1 may be 
a maladaptive hypoxic response that could be therapeutically targeted by PPARg activation to 
improve uteroplacental blood flow in hypoxic pregnancy. 
Our hypoxic protocol effectively reduced fetal weight and was accompanied by placental 
insufficiency, as the ratio of fetal to placental weight was reduced. These effects are similar to 
what we and others have seen in animal models of hypoxic pregnancy (37, 39, 114, 120). 
PPARg activation with TGZ was a potent vasodilator in isolated uterine arteries from 
both normoxic and hypoxic mice. This is consistent with reports that pharmacologic PPARg 
modulation alters vascular function and its activation is beneficial for improving blood flow. 
Namely, PPARg activation prevented fetal growth restriction (120, 148) and improved vascular 
function in rodent preeclampsia models (137, 148). Antagonizing PPARg was sufficient to 
reduce uterine artery vasodilation (136, 138). Inhibition of nitric oxide production with L-NAME 
blunted the vasodilatory effects of TGZ in uterine arteries from both groups, but the maximal 
vasodilation achieved was only blunted by L-NAME in normoxic mice, revealing less nitric 
oxide production in hypoxic mice. This is consistent with previous findings in animal models 
(76, 97, 99) and our recent human studies (100). Here we report a more potent effect of PPARg 
activation in hypoxic uterine arteries. Our studies (32, 120) and others’ (144-147) have shown 
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that PPARg is downregulated by hypoxia. We suggest that PPARg activation may be 
downregulated by hypoxia in the uterine artery in this model, thus resulting in a more sensitized 
response to pharmacologic PPARg activation in uterine arteries from hypoxic mice. 
We considered that the increased sensitivity of hypoxic uterine arteries to TGZ-induced 
vasodilation may also be due to elevated ET-1 signaling with hypoxia. Our rationale for this 
hypothesis was 3-fold. First, hypoxia augments ET-1 signaling, as circulating ET-1 was higher in 
HA pregnancy than low altitude pregnancy (150). Higher ET-1 has been associated with lower 
birth weight in HA pregnancy (95). Secondly, PPARg pathway activation directly suppresses 
synthesis of ET-1 (66, 67). Therefore, if the molecular target of PPARg, ET-1, is increased in 
hypoxic uterine arteries, then TGZ would have a greater effect in reducing ET-1 in these tissues, 
thereby having a greater vasodilatory effect overall. Third, as evidenced by the greater effect of 
L-NAME in blunting the maximal TGZ response in normoxic compared to hypoxic mice, 
mechanisms controlling vasoreactivity were altered by hypoxia, and it is likely that 
vasoconstriction would also be regulated differentially with hypoxia. 
Consistent with our hypothesis, uterine artery ET-1-induced vasoconstriction was greater 
in hypoxic mice compared to normoxic mice, with a larger maximal ET-1 response. This is 
consistent with higher levels of ET-1 in hypoxic pregnancy that others have measured (95, 150). 
However, these measurements do not look only at associations between ET-1 expression and 
birth weight; these functional data of the uterine artery contractile response to ET-1 are more 
valuable and give us information about the changes in ET-1 sensitivity and in vivo function of 
the uterine arteries of hypoxic mice. As ET-1 is normally downregulated during pregnancy as 
part of the rise in uteroplacental blood flow required for fetal growth (133), elevated ET-1 
signaling is likely contributing to the IUGR induced by hypoxia in this model. Importantly, 
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PPARg activation was sufficient to blunt the ET-1 response in both normoxic and hypoxic mice; 
this is reassuring when considering therapeutically targeting PPARg to improve uteroplacental 
blood flow. 
 In addition to the uterine artery, placental blood flow is a major determinant of nutrient 
and oxygen delivery to the fetus. We looked at expression of ET-1 receptors A and B in the 
placenta of normoxic and hypoxic mice to determine whether increased ET-1 signaling, and thus 
increased contractility, might be present in the hypoxic placentas to restrict nutrient delivery to 
the fetus. Indeed, we observed increased expression of both ET-1 receptors A and B in the 
junctional and labyrinthine zones of the placentas from hypoxic mice, suggesting increased 
contractility in the portion of the placenta important for nutrient exchange between the dam and 
fetus. Our previous data in a similar murine model reported no change in placental vascular 
density or total vascular area with hypoxia exposure (120); these new data suggest that although 
the vessel number is similar, the in vivo contractile response might be augmented and restrict 
nutrient delivery across the placenta. These findings are consistent with our previous findings 
that placental PPARg protein levels are lower with hypoxia (120), since PPARg is an antagonist 
of ET-1 signaling. 
 Interesting questions that remain include the role of PPARg’s actions on maternal 
metabolism, namely regulation of glucose homeostasis or nutrient transporters (42, 147, 151, 
152) in protecting or preventing fetal growth in hypoxic pregnancy. Also, while their main target 
is PPARg, thiazolidinedione drugs including TGZ also directly activate AMPK by a cell-
autonomous effect and indirectly by increasing release of adiponectin (85, 153). The role of 
AMPK activation in the effects of PPARg we observed here warrant further investigation. 
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 In these first studies of the functional effects of PPARg activation in isolated uterine 
arteries, we have provided further evidence that PPARg is a potential therapeutic target for 
improving uteroplacental perfusion which could be used in cases of hypoxic pregnancy including 
at HA. PPARg agonists are already used clinically to treat type II diabetes and polycystic ovarian 
syndrome (154, 155), so their safety and efficacy have been established in non-pregnant women. 
Further studies are needed to determine PPARg agonists’ mechanism of action specifically in 
pregnant animal models. Our findings provide evidence that a uteroplacental target of PPARg is 
downregulation of ET-1, which is elevated by hypoxia, providing support for PPARg 
manipulation in hypoxic pregnancy.  
Our finding that PPARg can regulate murine uterine artery vasoreactivity and hence 
maternal-fetal nutrient and oxygen exchange has the potential to open new avenues for 
prevention and/or treatment of IUGR, regardless of altitude. Ongoing studies will also determine 
the ability of PPARg activation to regulate vasoreactivity of human resistance vessels. This and 
ongoing studies will provide important mechanistic knowledge about the effect of chronic 
hypoxia on maternal vasculature in the absence of overt pathology as well as under conditions of 
clinically-defined IUGR, known to be an important determinant of cardiovascular disease later in 
life. Together these studies address calls for investigating PPARg agonists in treatment of 
vascular disorders of pregnancy (156) in order to contribute to development of IUGR 
interventions using existing pharmacologic compounds. 
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CHAPTER V 
PHARMACOLOGIC ACTIVATION OF PEROXISOME PROLIFERATOR-
ACTIVATED RECEPTOR GAMMA (PPARg) PROTECTS AGAINST HYPOXIA-
ASSOCIATED FETAL GROWTH RESTRICTION2 
Introduction 
Intrauterine growth restriction (IUGR) increases the risk of stillbirth 4-fold and neonatal 
death 8 to 20-fold (23). The adverse impact of IUGR extends across the lifespan, increasing the 
likelihood of disease in childhood as well as obesity, metabolic syndrome and cardiovascular 
disease in later life (127-129). IUGR and preeclampsia, a hypertensive disorder of pregnancy 
that shares key pathophysiologic features with IUGR (157) (158-160), often coexist. Together, 
these vascular disorders of pregnancy account for nearly 30% of premature deliveries (130, 131) 
with an annual cost in excess of $2.1 billion for short-term care in the United States alone (126). 
Despite its public health significance, the underlying pathophysiology of IUGR remains unclear 
and no effective prevention or treatment strategies exist. Among the numerous determinants of 
IUGR is the chronic hypoxia of high-altitude (HA, ³ 2500m) residence. Specifically, HA reduces 
birth weight and increases the incidence of IUGR 3-fold due, primarily, to a leftward shift of the 
birth-weight distribution rather than shortened gestation (17, 18, 132). Doppler indices of fetal 
brain sparing indicate that IUGR is the primary cause of lower birth weights at HA (21, 22). For 
this reason, investigations of HA pregnancy are uniquely poised to identify the physiologic and 
molecular mechanisms by which hypoxia influences fetal growth. 
                                               
2 Chapter V was taken in its entirety with permission from: Lane (Coates), SL et al., FASEB, In 
Press. 
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Normal fetal development depends on the adequate delivery of oxygen and nutrient-rich 
blood to the uteroplacental and fetoplacental circulations. To meet increasing metabolic demands 
of the fetus across gestation, pregnancy prompts extensive adaptations of the maternal 
cardiovascular system, lowering uteroplacental vascular resistance and permitting a >10-fold rise 
in blood flow throughout gestation (133). Placental factors also contribute to a reduction in 
uteroplacental vascular resistance. Specifically, during early human gestation, extravillous 
trophoblasts (invasive placental cells derived from the cytotrophoblast) migrate through the 
decidua to initiate extensive vascular remodeling of the uterine spiral arteries; this process is 
critical for establishing the placental perfusion (161). Placental hypoperfusion, a common 
pathophysiologic feature of IUGR and preeclampsia, has largely been attributed to impaired 
trophoblast differentiation, incomplete spiral and myometrial artery remodeling, reduced 
fetoplacental neovascularization (40), minimal branching of the villi capillaries (162) (162-164), 
and reduced uterine artery blood flow (165). In human (74, 95, 96, 134) and experimental animal 
models (38, 39, 166-168), hypoxia-induced IUGR is associated with reduced uteroplacental 
blood flow, although evidence also supports the involvement of placental factors. We propose 
that PPARg plays a central role for the effect of hypoxia to reduce fetal growth.  
PPARg is a ligand-activated transcription factor of the nuclear hormone receptor 
superfamily that governs gene expression by forming a heterodimeric complex with the retinoid 
X receptor at the regulatory region in target genes. While predominantly recognized for its role 
in metabolic homeostasis (62),  PPARg is vital for establishing the uteroplacental villous 
circulation (63, 64), modulating vasoreactivity by suppressing the synthesis of the potent 
vasoconstrictor endothelin-1 (66, 67), increasing nitric oxide production (68, 69), and regulating 
placental vascularization (65). Consistent with these functions, PPARg is abundantly expressed 
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in the labyrinthine zone of the rodent placenta (70), porcine placental vascular endothelial cells 
(169), as well as human trophoblast (63, 139) and vascular smooth muscle cells (140, 141). 
Abundant evidence implicates PPARg in the development of IUGR and/or preeclampsia 
(136, 138, 146, 170). In humans, for instance, placental PPARg mRNA expression is 2-fold 
lower in IUGR cases compared to controls and is directly related to fetal weight (146).   In recent 
work, we found that maternal HA (3600m - 4100m) residence during pregnancy downregulates 
the expression of key PPARg pathway genes in maternal peripheral blood cells and that this 
effect occurred in association with reduced birth weight and head circumference (32). In support 
of our findings, hypoxia attenuates PPARg expression in several human (140, 141, 171) and 
murine (172) cells types. Here, we use an experimental murine model to 1) determine whether 
hypobaric hypoxia reduces placental PPARg protein expression and diminishes placental 
vascularization in association with lower fetal weight and 2) determine whether dietary 
supplementation with a selective synthetic PPARg agonist (pioglitazone; PIO), during the latter 
portion of pregnancy protects against hypoxia-associated IUGR and normalizes placental 
vascularization. Emphasizing the translational potential of such studies, pharmacologic PPARg 
agonists are approved for human use to enhance insulin sensitivity in metabolic disease and 
polycystic ovarian syndrome (154, 155), and are the focus of clinical trials to reduce the risk of 
stroke or myocardial infarction (173). Further, renewed calls for evaluating the utility of PPARg 
agonists for the treatment of vascular disorders of pregnancy have been issued (156). We 
considered that the present studies may therefore accelerate the development of interventions 




Materials and Methods 
Experimental Animals, Treatments, and Exposures 
All murine experiments were approved by the Institutional Animal Care and Use 
Committee of the University of Colorado Denver and were consistent with the National Research 
Council’s Guide for the Care and Use of Laboratory Animals (84). 
Nulliparous C57/BL6 females and males (Jackson Labs) were paired overnight under 
standard conditions (12 h light-dark cycles at 23˚C and 60% humidity) in the animal care facility 
at the University of Colorado Denver Anschutz Medical Campus. Confirmation of mating was 
defined by the presence of a copulatory plug and considered as gestational day (149) 0.5. 
Pregnant dams were randomly assigned to receive either a control diet (“Controls”) (AIN-76A, 
Test Diet) or a PPARg agonist diet (“PIO”) (AIN-76A w/ 0.05% Actos containing 0.0125% 
pioglitazone HCl, Test Diet) under normoxic (4) or hypoxic (Hx) conditions, generating four 
study groups for comparison: Control-Norm, PIO-Norm, Control-Hx, and PIO-Hx. Activation of 
PPARg nuclear receptors occurs via natural PPARg ligands or pharmacologic compounds 
including thiazolidinediones (e.g., pioglitazone, rosiglitazone, troglitazone) (174). Pioglitazone 
was selected for this study given that the compound is a high-affinity, selective agonist for 
PPARg and is widely used for the treatment of type II diabetes (175, 176). 
For all animals, exposures and experimental diets began on GD 14.5. For the Norm and 
Hx groups, dams were placed into a normobaric chamber at a simulated altitude of 0 feet (PB 
~760 mmHg) or a hypobaric chamber at a simulated altitude of ~15,000 feet (PB ~460 mmHg), 
respectively. The PIO dose chosen was based on preparatory work in which the effect of three 
different PIO concentrations (0.05%, 0.025% and 0.0125%) on fetal viability were compared. 
Normoxic dams receiving the 0.05% or 0.025% PIO diet had significantly reduced fetal 
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numbers, whereas the 0.0125% PIO dose did not affect fetal number. All groups were fed ad 
libitum and had free access to water at all times. On GD 18.5, the dams were weighed and 
subsequently euthanized by CO2 inhalation followed by cervical dislocation. Immediately 
postmortem, the gravid uterus and uterine vasculature were carefully removed and placed in a 
dissecting dish containing cold, phosphate buffer solution (PBS, Thermo Fisher Scientific) with 
protease and phosphatase inhibitors (Sigma Aldrich). The number of fetuses were noted, fetuses 
and their placentas weighed separately without membranes and umbilical cords, and fetal 
biometry (crown-rump length and biparietal diameter) recorded. 
Biological Specimen Collection 
Within ten minutes of euthanasia, whole placentas were washed in cold PBS and cut into 
two equal portions. One half of the placenta was fixed in 4% paraformaldehyde, embedded in 
paraffin and sectioned to visualize the entire thickness of the placenta from the decidua to the 
chorionic plate in a single section. These sections were used to assess the effect of PIO and 
hypoxia on placental vascularization. The remainder of the placenta was snap frozen in liquid N2 
and stored at -80oC for Western blotting for semi-quantitative measures of PPARg protein 
expression. Given evidence that PIO increases the phosphorylation of adenosine monophosphate 
kinase (AMPK) in several tissues, including skeletal muscle (177) and adipose (178), placental 
p-AMPK protein levels were also evaluated to determine whether PIO treatment affected the 
organ of interest. 
Placental PPARg and p-AMPK Protein Expression by Western Blot 
Placental tissue was mechanically homogenized in Meso Scale lysis buffer (150mM 
NaCl, 20mM Tris pH 7.5, 1mM EDTA, 1mM EGTA, 1% Triton X-100) containing a mixture of 
water-soluble protease inhibitors with broad specificity for the inhibition of serine, cysteine, 
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aspartic and metalloproteases (Halt Inhibitor Cocktail, Thermo Fisher Scientific) using a 
sonicator. Protein concentration was determined using the Pierce BCA Protein Assay Kit (Pierce 
Biotechnology). PPARg protein expression was analyzed in placental tissue homogenates using 
commercial antibodies (2535S, Cell Signaling) with beta actin (13E5, Cell Signaling) as the 
loading control. Briefly, protein (15 µg/lane) was denatured, separated by SDS-PAGE on a 4-
20% Mini-PROTEAN TGX Precast Gel (BioRad), then transferred to nitrocellulose membrane 
for 90 minutes at 30V at 4oC. All block steps and incubations were performed in Li-Cor Odyssey 
TBS Blocking Buffer (Li-Cor Biosciences). Membranes were exposed to primary antibody 
overnight at 4°C and to Li-Cor fluorescent secondary antibodies for one hour at room 
temperature. Membranes were imaged and analyzed using Image Studio software on a Li-Cor 
Odyssey CLx. Data are presented as fluorescent signal normalized to beta actin. 
Assessment of Placental Vascularity  
Formalin-fixed, paraffin-embedded placental tissue sections (5-μm) were used for 
haemotoxylin and eosin (H&E) and CD34 (vascular endothelial marker) staining, processed for 
histological staining and immunohistochemistry (IHC), and imaged as described previously (179, 
180) to assess placental vascularity. The CD34-stained slides were quantified for vascularity 
using the Matlab Image Processing Toolbox as previously described (181). Field of views were 
captured across the placenta at 20x magnification. Briefly, image analysis measured the area of 
CD34 using brightfield colorimetric thresholding to identify vessels stained as positive for 
endothelial marker. The vascular-mask threshold identified individual vessel density and area. 
Vessel density was defined by the average number of vessels per unit area of tissue per image. 
Vessel area of an image was defined as the total area of vessels stained in an image in square 
microns per field of view.  
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Data Analysis 
Continuous variables were tested for normality using the Kolmogorov-Smirnov test. 
Two-way analysis of variance was used to determine the effects of PIO treatment and hypoxic 
exposure on maternal weight, fetal biometry, fetal weight and placental characteristics. All 
models included PIO treatment and exposure as main effects and an interaction term for PIO x 
exposure. Sidak’s test was used to identify between-group differences. Individual dam and fetal 
data are reported as an average within each group (e.g., Control-Norm). All analyses were 
conducted using GraphPad PRISM (GraphPad Software, Inc). Data are expressed as the mean ± 
the standard deviation, and sample sizes for each comparison are provided in the table and figure 
legends. Statistical differences were considered significant when the two-tailed P < 0.05 unless 
specified otherwise, and trends were reported when 0.05 < P < 0.10.  
Results 
In this section, results are structured to compare first, the effect of 1) Hx on our primary 
outcomes of interest for each treatment group (Control and PIO), and second the effect of PIO 
treatment within each exposure group (Norm and Hx). Significant interaction effects (Hx x PIO) 
indicate that the effect of hypoxia on a given variable differs between control- and PIO-treated 
animals.  
Effect of Hx and PIO on Maternal and Fetal Characteristics 
Prior to the initiation of exposures and experimental diets (GD 8.5), dam weight was 
equivalent among all groups (Table V.1). At the time of tissue harvest (GD 18.5), Control-Hx 
dams weighed 27% less than Control-Norm dams, whereas PIO-Hx and PIO-Norm dams were of 
similar weight (Table V.1). PIO-Hx dams weighed 16% more than Control-Hx, indicating that  
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Table V.1. Effect of Hypoxia and Pioglitazone on Dam and Fetal Characteristics 
 
         Control  PIO P-value 
 













NS NS NS 
Dam weight, 









<0.0001 NS <0.0001 








<0.05 NS NS 








<0.0001 <0.0001 <0.05 








<0.05 NS <0.05 
 
 
       
Abbreviations: Gestational day (149), grams (g), crown-rump length (CRL) and biparietal 
diameter (BPD). Data were analyzed by 2-way ANOVA with Sidak’s multiple comparisons to 
detect sources of difference. Supercripts a, b, c and d are used to denote values that are 
significantly different from Control-Norm, Control-Hx, PIO-Norm and PIO-Hx, respectively. 
Sample sizes: dams (Control-Norm, n = 6, Control-Hx, n = 5, PIO-Norm, n = 6, PIO-Hx, n = 
10), fetal characteristics (Control-Norm, n = 54, Control-Hx, n = 26, PIO-Norm, n = 43, PIO-Hx, 
n = 63).  
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the effect of Hx to reduce dam weight was blunted with PIO treatment (interaction effect: 
Hypoxia x PIO, P < 0.0001).  
While Hx reduced fetal number overall, there was no statistically significant effect in 
control or PIO animals considered separately (Table V.1). Similarly, the number of resorptions 
visible at the time of harvest was unaffected by Hx or PIO (data not shown). In Controls, Hx 
reduced fetal weight 21% (P < 0.001) compared to a 9% reduction in dams treated with PIO (P < 
0.05; Figure V.1A). As a result, PIO-Hx fetuses weighed 16% more than Control-Hx (P < 
0.001). In contrast, fetal weight was similar between the Control-Norm and PIO-Norm groups. 
Hx was associated with reduced fetal crown-rump length in Controls, whereas this was not the 
case in fetuses of dams treated with PIO. Specifically, compared to Control-Norm, fetal crown-
rump length was greater in PIO-Norm and PIO-Hx (Table V.1). Hx had no effect on fetal 
biparietal diameter in Controls, whereas values were greater for PIO-Hx compared to PIO-Norm.  
Effect of Hx and PIO on Placental Weight and Placental Insufficiency  
Placental weight was unaffected by Hx in control or PIO dams (Figure V.1B). Under Hx 
conditions, placental weight was lower in PIO vs. Controls (P < 0.05, Figure V.1B), whereas 
there was no difference between and Control and Pio groups under Norm conditions. Hx 
increased placental insufficiency, as assessed by the ratio of placental to fetal weight, in control 
vs. PIO dams (Figure V.1C). Moreover, PIO dampened the effect of Hx to increase placental  
insufficiency (interaction effect of Hx x PIO, P < 0.01; Figure V.1C). 
Effect of Hx on Placental PPARg Protein Expression  
In Controls, placental PPARg protein expression was 46% lower under Hx conditions as 




Figure V.1. Effect of Hx and PIO on Fetal and Placental Weight. Fetal weight, placental 
weight and placental to fetal weight ratios were compared between treatment groups (PIO and 
control) and exposure groups (Norm and Hx) using 2-way analysis of variance and Sidak’s 
multiple comparisons tests to identify sources of difference. Data are shown as individual values 
for fetuses A) PIO protected against the effect of Hx to reduce fetal weight. In Controls, Hx 
reduced fetal weight 20.6% vs. a 9.3 % reduction in the PIO group. Notably, while fetuses of 
dams treated with PIO weighed 16 % more than Controls under Hx conditions, there was no 
difference in fetal weight between treatement groups under Norm conditions. B) Overall, 
placental weight was greater under Hx compared to Norm (main effect, Hx); considering PIO 
and Controls group separately, however, placental weight was unaffected by Hx. PIO reduced 
placental weight overall (main effect, PIO) and under Hx conditions. C) In Controls and dams 
treated with PIO, Hx increased placental insufficiency, as assessed by the ratio of placental to 
fetal weight.  Notably, the magnitude by which Hx increased placental insufficiency was reduced 
with PIO treatment (interaction effect: Hx x PIO). Solid lines with asterisks indicate significant 
post-hoc comparisons: * p<0.05, *** p<0.001 and **** p<0.0001. Significance values for the 
main effects of Hx, PIO, and the interaction of Hx x PIO are shown within each plot. Sample 
sizes: Control-Norm, n = 54, Control-Hx, n = 26, PIO-Norm, n = 43, PIO-Hx, n = 63. 
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compared between PIO and Controls given that PIO selectively stimulates the PPARg nuclear 
receptor to modulate the transcription of downstream genes rather than affecting PPARg itself. 
Given that thiazolidinediones, including PIO, activate AMPK, we assessed placental p-AMPK 
protein in each group to determine whether PIO was acting on the placenta, the organ of interest. 
In Controls, placental p-AMPK protein levels trended lower under Hx conditions (Figure V.2B).  
Conversely, placental p-AMPK protein levels were elevated in PIO-Norm vs. Control-
Norm (P < 0.05) and trended higher in Hx conditions as well (Figure V.2B), suggesting that PIO 
but not hypoxia activated AMPK.  
Effect of Hx and PIO Treatment on Placental Vascularization 
Hx had no effect on placental vascularization as assessed by vessel density or mean 
vascular area per field of view, in Controls or PIO (Figure V.3A, B). In contrast to our 
expectations, however, placental vascular density and mean vascular area were lower in PIO-Hx 
compared to Control-Hx (Figure V.3A, B). Mean placental vessel size was unaffected by PIO 
treatment (P = NS, all comparisons). Representative histology images of H&E and CD34 
staining of placental sections for each group are shown in Figure V.3C, with the labyrinthine 
and junctional zones distinguished. Qualitatively, placental vascularization appears markedly 
sparse and diffuse compared in PIO-Norm and PIO-Hx compared vs. Control-Norm and Control-
Hx (Figure V.3C).  
Discussion 
The PPARg pathway plays a vital role for several processes required for successful 
pregnancy and has been implicated in the development of IUGR and preeclampsia. In this first 
report to explore the role of PPARg in hypoxia-induced IUGR, we found that exposure to 




Figure V.2. Effect of Hx on Placental PPARg Expression, and Effect of Hypoxia and PIO 
on Placental AMPK Activation. Ratios of PPARg protein expression to b-actin expression were 
compared between Control-Norm and Control-Hx using Student’s t-test. Ratios of p-AMPK to 
b-actin expression were compared between treatment groups (PIO and Control) and exposure 
groups (Norm and Hx) using one-way analysis of variance and Sidak’s multiple comparisons test 
to identify sources of difference. A) In untreated animals, hypoxia reduced PPARg protein 
expression in the placenta by half (P < 0.05). B) In untreated animals, placental p-AMPK was 
81% lower with hypoxia (P < 0.05). In normoxic animals, PIO treatment tripled placental p-
AMPK (P < 0.05). In hypoxic animals, p-AMPK trended higher with PIO treatment but 
remained lower than levels in normoxic, untreated placenta. Sample sizes: Control-Norm, n = 5, 









Figure V.3. Effect of Hypoxia and PIO Treatment on Placental Vascularization. Placental 
vascular density and mean vascular area were compared between groups (Control-Norm n=4, 
Control-Hx n=11, PIO-Norm n=4, PIO-Hx n=14) using 2-way analysis of variance and Sidak’s 
multiple comparisons tests to identify sources of difference. A) Neither vessel density (the 
number of vessels per um2) nor the mean vascular area per field of view was affected by 
hypoxia; this was true for Controls and PIO-treated animals. Placentas of PIO-treated animals 
showed reduced vessel density under normoxic and hypoxic conditions, as well as lower mean 
vascular area in hypoxia. Solid lines with asterisks indicate significant post-hoc comparisons: * 
p<0.05, ** p<0.01. B) Representative histology images of H&E and CD34 staining of placental 
sections for each exposure and treatment group, with the labyrinthine (LZ) distinguished; 
qualitatively, placental vascularization of PIO-treated animals appears markedly sparse and 
diffuse compared to Controls under normoxic and hypoxic conditions.  
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association with diminished fetal growth and evidence of placental insufficiency. Our findings 
further indicate that dietary supplementation with PIO, a selective PPARg agonist, protects fetal 
growth under hypoxic conditions. Given evidence that PPARg has potent angiogenic properties 
in the placenta, we hypothesized that pharmacologic activation of PPARg would increase 
placental vascularization. Contrary to our expectations, placental vascularization, particularly 
within the labyrinthine zone, decreased with pioglitazone treatment under normoxic and hypoxic 
conditions. Based on these findings, we propose that the mechanism by which PPARg activation 
in late pregnancy acts to protect against hypoxia-induced fetal growth restriction is not the result 
of proangiogenic effects in the placenta, but rather may be due to the metabolic properties of 
PPARg or its effects on vascular function. 
Our hypoxic model induced a 21% reduction of fetal weight, a magnitude of growth 
restriction similar to the 21% to 26% reduction seen with a near term, 5-day normobaric hypoxia 
exposure to 10% O2 in mice (39, 168). Other reports, however, suggest that exposure to 12% O2 
from GD 14.5 to 18.5 (167) or 13% O2 for the entirety of gestation (87) induces a more modest 
degree of fetal growth restriction (7% and 12%, respectively). We consider it possible that such 
variability may be due, in part, to the fact that the mice in our study spent early pregnancy at 
moderate altitude (Denver, Colorado; 1609m) rather than sea level and/or that the effect of 
normobaric hypoxia on fetal growth differs slightly from that of hypobaric hypoxia. Existing 
literature regarding the effect of hypoxia on placental weight in mice also varies, with some 
studies reporting greater values with hypoxia (87) and others, including our present data, 
showing no effect (39, 166, 168). In humans, reports of placental weight also vary, with some 
reports indicating higher (90),  lower (92), or equivalent weights (182, 183) at high versus low 
altitude. Consistent with others’ work in rodents (39, 166, 168), we found that hypoxia increased 
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the ratio of placental to fetal weight, indicating greater placental insufficiency under hypoxic 
conditions. 
In our model, exposure to hypobaric hypoxia had no effect on placental vascularization, 
as determined by vessel density, mean vascular area or vessel number. In murine models, the 
effect of late-gestation hypoxia on placental vascularity has been reported to decrease or increase 
(166-168, 184, 185). In humans, greater placental vascularization has been reported at high 
altitude (182, 183).  For instance, the intermediate and terminal villi of placentas obtained from 
women of Kirghiz ethnicity residing at high altitudes (2200m - 2800m) tended to have a higher 
volume fraction of fetal capillaries and increased capillary length density compared to their 
lowland (760m) counterparts. In contrast, comparisons between placentas obtained from 
uncomplicated pregnancies at high altitudes in Colorado (3100m) have decreased capillary 
volume, and unchanged capillary length density, total length and diameter compared to sea level 
(186). Variability between studies with respect to placental vascularization may be due, in part, 
to differences in population ancestry and/or the altitudes being compared.  
Our data indicating that hypobaric hypoxia suppressed placental PPARg protein 
expression agrees with existing reports of lower PPARg mRNA and/or protein expression in 
isolated murine and human cells following exposure to low oxygen environments, and evidence 
that PPARg is regulated, in part, by the hypoxia-inducible factor 1a (HIF1a). PPARg mRNA and 
protein expression, for example, is attenuated in murine trophoblasts incubated under 2% O2 
(172). Indicating that this effect is not limited to the placenta, PPARg mRNA and/or protein 
expression is also suppressed with hypoxia in human pulmonary vascular smooth muscle cells 
(140), adipocytes (171), and proximal renal tubular cells (141). Our recent human studies further 
show that high-altitude residence (3600m) downregulates PPARg pathway gene expression in 
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maternal peripheral blood mononuclear cells during pregnancy (187). Further, a recent study 
identified a highly conserved hypoxic response element (HRE) located 1042 base pairs upstream 
of the PPARg transcriptional start site (188). Specifically, by transfecting normal human adult 
mesothelial cells with a mouse wild-type promoter and a PPARg promoter fragment mutated at 
the proposed HRE site, Krishnan et al. showed that while the mutant PPARg-HRE promoter was 
unresponsive to the coexpression of a constitutively-active form of HIF1a (“HIF1aDPro”), the 
wild-type PPARg promoter responded in a HRE-dependent manner (188), indicating that PPARg 
is a direct HIF1a target. However, the relationship between HIF1a and PPARg appears to be 
complex and tissue specific. Activation of HIF1a inhibits PPARg gene transcription during 
adipocyte differentiation (171), whereas in cardiomyocytes HIF1a activation increases PPARg 
expression (188). In murine trophoblast stem cells, however, hypoxia has been reported to 
repress PPARg expression in a HIF1a-independent fashion (172). Acknowledging that the 
transcriptional activity and molecular responses of isolated cells grown in culture likely differ 
from the in vivo condition, further studies are needed to determine whether the effect of impaired 
maternal oxygenation on reducing placental PPARg expression that was observed in our study 
occurred via HIF1a-independent mechanisms.  
Abundant human and experimental evidence support the link between reduced placental 
PPARg protein expression and a hypoxia-induced reduction of fetal weight. In particular, human 
placental PPARg gene and/or protein expression is lower in IUGR cases compared to controls, 
and directly related to fetal weight (146, 147). Further, while IUGR and preeclampsia are distinct 
entities, given that the two conditions share pathophysiological features and often occur in 
tandem, it is notable that a dominant loss-of-function mutation in the ligand-binding domain of 
PPARg is associated with the development of severe preeclampsia (170) and reduced PPARg 
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ligand levels can be detected in the maternal circulation prior to preeclampsia diagnosis (144, 
145). Strengthening these associations, treatment with a PPARg agonist (troglitazone) abolished 
hypertensive responses to angiotensin II infusion during pregnancy and normalized fetal growth 
in a genetic mouse model (Rgs5 +/-) known to be susceptible to hypertension and IUGR (148). 
Conversely, antagonizing PPARg via dietary supplementation with GW9662 or intraperitoneal 
delivery of T0070907 decreased fetal growth in rats (136, 138). Given recent calls for evaluating 
the utility of PPARg agonists for the treatment of vascular disorders of pregnancy, including 
IUGR and preeclampsia, our observation that pharmacologic PPARg activation partially restores 
fetal growth under hypoxic conditions is compelling.  
Here, we considered that activation of the PPARg pathway may protect fetal growth by 
increasing placental vascularization. Our rationale for this approach was twofold. First, in 
humans, branching of mature intermediate villi is largely absent in IUGR placentas with absent 
or reversed end diastolic velocity, and the terminal capillaries appear thin and elongated (162-
164, 189). In line with these data, fetoplacental neovascularization is impaired at GD 19 in a 
transgenic murine model of preeclampsia accompanied by fetal growth restriction (40). Taken 
together, these published data highlight the potential importance of sparse placental 
vascularization for IUGR. Second, existing evidence suggests that pharmacological activation of 
PPARg increases placental vascularization. Specifically, in human placental explants, the PPARg 
agonist rosiglitazone increases vascularization of the placental villi, increasing capillary length 
and vessel size (65). Such effects appear to be mediated through a placental, endocrine gland-
derived vascular endothelial growth factor (65). Further, in isolated porcine placental vascular 
endothelial cells, rosiglitazone not only promotes tube-like formation, cellular proliferation and 
migratory capabilities but also increased mRNA expression of vascular endothelial growth factor 
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(VEGF) and its receptor (VEGFR2) (169). In contrast to our expectations, however, PPARg 
activation reduced vascularization of the labyrinthine zone in both normoxic and hypoxic 
conditions. One consideration may be the fact that the effect of PPARg activation on 
vascularization varies across gestation. In experimental animal models, daily administration of 
the PPARg agonist rosiglitazone via needle gavage from GD 4.5 to 16.5 reduced placental 
vascularization and the expression of proangiogenic factors (169). For this reason, our study was 
purposely designed to initiate the pharmacological intervention during latter pregnancy, since 
this is a time that is roughly equivalent to the second and third trimester of human pregnancy. In 
support of this design, while placental growth is limited during the last half of gestation when 
IUGR is commonly detected (190-192), the increasing metabolic demands of the developing 
fetus during this timeframe are met, in part, by enhanced placental function and dramatic 
branching growth of the fetoplacental capillary bed (193). However, our current results do not 
support the hypothesis that the effect of pioglitazone for preserving fetal growth is mediated by 
placental vascularization. Rather, we interpret our findings are due to global effects, perhaps 
metabolic or maternal blood flow related effects of PPARg agonist supplementation, given that 
pioglitazone was administered via dietary supplementation rather than those targeted specifically 
to the placental vasculature.  
An alternate mechanism by which PPARg may protect fetal growth relates to its role in 
the regulation of vascular function. Normal pregnancy initiates extensive maternal 
cardiovascular responses that collectively serve to sustain a sufficient level of uteroplacental 
perfusion required for fetal development. Uterine artery diameter and blood flow, for instance, 
rise profoundly across gestation; such effects are due, in part, to changes in the production and/or 
activity of vasodilators (e.g., nitric oxide, NO, and large‐conductance Ca2+-activated K+ 
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potassium channels, BKCa) and vasoconstrictors (e.g. endothelin 1, ET-1) (133). At high altitude, 
the pregnancy-associated rise in uteroplacental blood flow is diminished, an effect that is directly 
associated with slowed fetal growth and IUGR (75, 95, 96, 134). Experimental animal studies 
indicate that hypoxia reduces uterine vasodilator responses, exaggerates myogenic tone (due, in 
part, to inhibition of BKCa channels), diminishes uterine artery eccentric growth, and reduces 
NO-induced uterine artery vasodilation (76, 77, 135). Suggesting a vasoprotective role for 
PPARg, activation of the PPARg pathway suppresses ET-1 synthesis and prepro-ET-1 expression 
in human vascular endothelial cells (66, 67). PPARg ligands also increase NO production via 
PPARg-dependent mechanisms (68). Specifically, PPARg promotes the interaction of heat shock 
protein 90 and endothelial NO synthase (eNOS) and increases eNOSser1177 phosphorylation (69). 
Evidence further indicates that PPARg regulates myogenic tone of the mesenteric artery via 
regulator of G protein signaling 5 (Rgs5)-mediated control of protein kinase C and BKCa channel 
activity (143). Further indicating vascular sites of action, in a rodent model of preeclampsia 
(reduced uterine perfusion pressure, RUPP), administration of rosiglitazone from GD 16 to 18 
improved mesenteric artery vasorelaxation (137). Conversely, antagonizing PPARg during 
pregnancy impairs vasodilation of radial uterine arteries and induces a constellation of 
preeclampsia-like symptoms including hypertension and endothelial dysfunction (136, 138). 
Thus, further study is warranted to determine the effect of PPARg activation on the 
vasoreactivity of uterine vessels responsible for uteroplacental perfusion. Other potential avenues 
for future research include experimental animal and human studies to determine whether PPARg-
mediated regulation of glucose homeostasis (42, 151, 152) and/or nutrient transporters (147) also 
influence fetal growth at high altitude.  
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Emphasizing the translational potential of our research, PPARg agonists including 
thiazolidinediones are widely used for enhancing insulin sensitivity in metabolic disease, and are 
the focus of clinical trials for reducing the risk of stroke or myocardial infarction (173). 
Additionally, next-generation PPARg agonists are already being used clinically for the treatment 
of type II diabetes and polycystic ovarian syndrome (154, 155). To maximize the therapeutic 
potential of PPARg agonists for vascular disorders of pregnancy, continued efforts are needed to 
(1) clarify the physiological role of PPARg activation during normal pregnancy, (2) identify the 
molecular pathways that govern PPARg activation and its downstream transcriptional targets in 
reproductive tissues and (3) determine whether the effects of pharmacologic PPARg agonists are 
due to the activation of PPARg itself or to off-target effects. Despite the complexity of PPARg 
signaling, its effects on placental structure and function and vasoregulation during pregnancy 
underscore its potential as a therapeutic target for improving pregnancy outcomes in cases of 
IUGR and vascular complications such as preeclampsia. Since our results suggest a lack of 
improved placental vascularization with late-gestation PPARg activation, ongoing studies will 





CONCLUSIONS AND DISCUSSION 
Summary and Conclusion 
 This work identifies AMPK and PPARg as ex vivo potent vasodilators of murine uterine 
arteries whose in vivo activation is sufficient to partially or fully prevent hypoxia-induced IUGR 
in mice. Further, the data presented here delineate effects of hypoxia correlating with reduced 
fetal weight, and thus improve understanding of pathological processes contributing to IUGR. 
Specifically, hypoxia induced greater uterine artery blood flow and, although hypoxia did not 
decrease placental vascular density or area, it altered placental signaling by reducing placental P-
AMPK and PPARg and increasing placental endothelin-1 receptor expression, which may 
indicate increased placental vascular resistance. These studies provide evidence that in vivo 
AMPK and PPARg activation are likely vasoprotective, as 1) in vivo AMPK activation with 
AICAR improved uterine artery blood flow measured by ultrasound, 2) in vivo AMPK inhibition 
with ComC reduced uterine artery diameter measured by ultrasound, 3) in vivo PPARg activation 
with pioglitazone prevented fetal growth restriction even though placental vascularity was 
reduced, and 4) the ex vivo ET-1 response was upregulated by hypoxia, and yet the ex vivo 
PPARg-induced vasodilation response was even more potent with hypoxia. These findings 
provide rationale for further evaluation of both AMPK and PPARg pathways as potential 
therapeutic targets in preventing IUGR. In this section, I will first discuss the implications and 
significance of my thesis work. Then, I will discuss possible future avenues of inquiry that result 




Vertically Integrated Protocol to Study Uterine Artery Physiology 
 These studies were the first example of a small experimental animal model in which the 
effects of hypoxia on uterine artery volumetric flow were studied. Our ability to obtain the 
uterine artery diameter and calculate flow was paramount in interpreting the effects of hypoxia 
and AMPK modulation on uteroplacental perfusion, as other measurements of uterine artery 
hemodynamics are not sufficient to describe flow. For example, pulsatility index is often used by 
clinicians as a description of flow through the uterine artery. However, these studies show a 
consistent reduction in the uterine artery pulsatility index in hypoxic dams, regardless of drug 
treatment, even though uterine artery blood flow is significantly elevated in AICAR-treated 
hypoxic dams. This is because rather than reduced resistance allowing for increased uterine 
artery blood flow with AICAR, there was an increase in the uterine artery index, or proportion of 
cardiac output flowing through the uterine artery. Obtaining uterine artery diameter allowed us to 
subsequently calculate the uterine artery index and identify this significant effect, as the ability 
of AICAR to selectively increase blood flow to the uterus is exciting when considering it as a 
therapeutic modality to treat or prevent IUGR. 
 Notably, we sometimes saw inconsistencies in effects of hypoxia or drug treatment on 
uterine artery ex vivo vasoreactivity compared to in vivo flow. We never saw opposite effects, 
but rather we sometimes saw only an effect on blood flow, such as in hypoxic mice treated with 
AICAR, in which we saw no change in ex vivo vasodilation in response to ACh or AMPK 
activation by A769662, but we did see increased in vivo uterine artery blood flow by Doppler 
ultrasound. In some cases the vasoreactivity and ultrasound data were conclusive, however; in 
hypoxic mice treated with ComC, there was a more potent ex vivo contractile response to 
phenylephrine, and there was a smaller uterine artery diameter measured by Doppler ultrasound. 
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These inconsistencies provide further support for the importance of gathering both in vivo 
volumetric flow data as well as ex vivo vasoreactivity data. 
Importance of Uterine Artery Blood Flow in Mediating Fetal Growth 
 The studies encompassed in this thesis provide evidence that regulation of uterine artery 
blood flow is a major contributing factor for fetal growth in our model of late-gestation hypoxia. 
When we treated mice in vivo with the PPARg agonist pioglitazone, we were able to prevent 
hypoxia-induced IUGR in the hypoxic mice even though placental vascularization was reduced. 
Based on this thesis work, we suggest that the ability of pioglitazone to improve fetal growth is 
through vasodilation of uteroplacental arteries and improved transport of nutrients to the fetus, 
showing that the uterine artery is a major determinant of overall blood flow to the fetus. Further, 
dams exposed to hypoxia upregulated their uterine artery blood flow in a short time period of 3 
days, from when they were exposed at E14.5 to when ultrasound was performed at E17.5, 
highlighting the physiologic importance of mechanisms regulating uterine artery blood flow in 
this model.  
 We are limited in the mouse to studying blood flow and vasoreactivity changes in the 
main uterine artery, upstream from the canonical sights of highest vascular resistance: the 
myometrial and placental vasculature. However, these observations of the importance of the 
main uterine artery blood flow are reassuring in that we are able to study vasculature that is 
important for protecting fetal growth in hypoxia. 
Nitric Oxide Signaling is Downregulated by Hypoxia 
 Nitric oxide is a key molecule in these studies. As its production in the vasculature is 
increased in pregnancy but downregulated by hypoxia, nitric oxide is an attractive target for 
improving vasodilation in hypoxic pregnancy. Both AMPK and PPARg upregulate the synthesis 
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of nitric oxide, which likely contributes to their actions as vasodilators in isolated murine uterine 
arteries as I have shown, providing support for their pharmacologic activation in cases of 
reduced uteroplacental perfusion. 
 Increasing evidence shows that the contribution of nitric oxide production to vasodilatory 
effects in the vasculature, including the uterine artery, is reduced in hypoxia; this has been shown 
in experimental animal models (76, 97, 99) and in humans (100). In this thesis work, we found 
that AMPK-, PPARg- or ACh-induced vasodilation was less dependent on increased NO 
production in hypoxia compared to normoxic mice, adding further support to this observation. 
Importantly, vasodilation by all three mechanisms was still effective in hypoxic mice, indicating 
that a different endothelial factor or a smooth muscle factor is contributing to their vasodilatory 
effects in hypoxic mice. 
Limitations 
 As mentioned above, utilizing a murine model limited us to studying the main uterine 
arteries, due to size constraints of smaller downstream resistance arteries. However, we did see 
effects of hypoxia and drug treatment on the main uterine artery vasoreactivity and flow, 
indicating that it is significantly contributing to fetal nutrient delivery. 
 A limitation in interpreting our data is that we did not collect information about fetal sex. 
Some studies show that maternal physiological responses and fetal outcomes vary based on fetal 
sex, and thus it might be interesting in the future to see whether effects of hypoxia or drug 
treatment in the placentas differed based on whether the matching fetus was male or female (82, 
167, 194-197). In the studies presented in this thesis, there is possibly evidence that effects of 
hypoxia in reducing fetal weight may be fetal sex-dependent. In Figures II.1 and IV.1, the 
average fetal weight in each litter in the normoxic group clusters closely with little variability; in 
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the hypoxic group there is greater variability in the average fetal weight per litter. This suggests 
that the proportion of each fetal sex per litter may have varied, contributing to a greater 
variability in average fetal weight, such that one sex was more sensitive to hypoxia-induced fetal 
growth restriction than the other sex. Based on prior reports, males might have been more growth 
restricted by hypoxia as they have been shown to be more sensitive to in utero insults (198-200).  
Future Avenues for Investigation 
 In these studies, I focused mainly on uterine artery vasoreactivity and blood flow. The 
rationale for this included that: 1) Hypoxia downregulates uterine artery blood flow. 2) Hypoxia 
downregulates nitric oxide production. 3) AMPK is a vasodilator through its role in activating 
endothelial nitric oxide synthase in addition to direct effects on vascular smooth muscle cells, 
and PPARg is a vasodilator as well by upregulating endothelial nitric oxide synthase and 
downregulating endothelin-1. Thus, since I was evaluating two signaling pathways that directly 
antagonized the effects of hypoxia on uterine blood flow, I focused there. However, other 
processes including immune cell function, redox balance, and potassium channels would likely 
also be affected by hypoxia and drug treatment and contribute toward regulation of uterine artery 
blood flow and fetal growth. 
Immune Cells 
 Further investigation is needed to determine why hypoxia in our model increased uterine 
artery blood flow. Future studies could address the contribution of immune regulator cells, which 
are important for vascular remodeling. Immune cells are specifically important in the pregnancy-
associated reduction of systemic vascular resistance; in one study maternal mesenteric arteries 
had increased stiffness postpartum in immune deficient mice compared to wild-type, and this 
was dependent on loss of CD8+ T cells (201). Conversely, in another study, natural killer cells 
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were injected systemically into immunocompromised mice and uterine artery resistance 
decreased as measured by Doppler ultrasound (202), indicating that immune cells are both 
necessary and sufficient for proper pregnancy-associated vascular regulation. Uterine natural 
killer cells have been well characterized in remodeling of uterine vasculature: they target the 
extracellular matrix and uterine vascular smooth muscle cells (203, 204), are unique from 
circulating natural killer cells, and depend on signals including nitric oxide (205). 
 Actions of immune cells that may be affected by hypoxia include reduced secretion of 
matrix metalloprotease-9, which is important for vascular remodeling (206) and has been shown 
to be reduced in the placenta, uterus, and uterine artery of a rat model of preeclampsia compared 
to healthy controls (207). It would be interesting to measure the levels of immune cells and their 
effector molecules and relate them to uterine artery blood flow and distensibility to see whether 
immune cells are having a pro- or anti-dilatory effect.  
Redox Regulation 
 An additional avenue of investigation is of effects of hypoxia and AMPK and PPARg 
pathway modulation on redox state. The hypoxia exposure of high-altitude residence is sufficient 
to decrease circulating oxygen levels, which alters redox balance. At an extreme altitude of 5800 
meters, the arterial partial pressure of oxygen is reduced by half compared to at sea level (208), 
impacting circulating and tissue levels of oxygen. Mitochondria consume up to 90% of cellular 
oxygen for oxidative phosphorylation and are therefore impacted by a reduction in an organism’s 
oxygen levels. It is likely, therefore, that mitochondrial function is affected in residents of high 
altitude, and that this could impact ROS generation and redox balance. Indeed, it has been shown 
that chronic hypoxia leads to increased ROS through altering the mitochondrial electron 
transport chain (209, 210). 
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 In times of cellular stress and high levels of ROS, AMPK leads to mitochondrial 
biogenesis and increased mitophagy of defective mitochondria in order to maintain balance 
between ROS production and destruction. AMPK also phosphorylates transcription factors 
which increase transcription of antioxidant pathways. For example, in vitro, AMPK 
phosphorylates the master transcription factor regulating antioxidant genes, Nrf2 (211). AMPK 
also maintains high levels of key metabolites with antioxidant effects such as NADPH through 
its inhibition of acetyl-coA carboxylase (212). Drugs that activate AMPK including AICAR have 
antioxidant effects (122). 
 At high altitude, increased antioxidant pathway activity—namely increased circulating 
super oxide dismutase—is associated with lower incidence of small for gestational age births 
(213). Since AMPK activators have antioxidant effects, it is necessary to evaluate effects of our 
model of hypoxia on ROS, and the effects of pharmacologic AMPK and PPARg manipulation in 
improving redox state. 
 Evidence has emerged that thioredoxin-interacting protein (TXNIP), an endogenous 
inhibitor of thioredoxin which is important in regulation of cellular sulfhydryl redox state and 
induces oxidative stress (214, 215), is regulated by AMPK (216, 217). Treatment with the 
AMPK activator AICAR, a drug used in the studies within this thesis, was sufficient to inhibit 
TXNIP gene expression and protein levels such that the authors concluded that nutrient 
regulation of TXNIP is dependent on AMPK (218). TXNIP has been shown to increase vascular 
dysfunction due to enhanced endothelial (219, 220) and vascular smooth muscle (221) 
inflammation, and reduction of endothelial signaling molecules including NO and vascular 
endothelial growth factor (VEGF) was associated with increased levels of TXNIP (219). Thus, 
one possible mechanism for AMPK’s effects in improving uterine artery blood flow may be due 
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to the downregulation of TXNIP. Further, as estrogen also downregulates TXNIP to promote 
vascular function (222), estrogen and AMPK may be having synergistic effects to improve 
uterine artery blood flow in AICAR-treated pregnant mice. 
Ongoing Human Studies 
 The Moore and Julian labs have ongoing investigational studies in human populations 
living at sea level (0m) in San Diego, CA, at HA (>2500m) in Summit County, CO, and at an in-
between altitude in Denver, CO (~1600m). While these studies are not interventional, they 
complement the murine studies described in this thesis, as the effects of the hypoxia of HA 
residence on uteroplacental signaling, blood flow, and vasoreactivity are being determined. 
Preliminary data suggest that AMPK activation is reduced by HA in the placenta and myometrial 
arteries (unpublished data), which is similar to the findings presented here. In myometrial 
arteries from the HA group, the contribution of NO production to effects of vasodilators was 
reduced compared to the Denver altitude group (100); this mirrors the murine findings presented 
here. Other findings in the human studies, however, differ from the results of the murine studies 
described in this thesis. For example, while PPARg activation by TGZ vasodilated murine 
uterine arteries more potently in mice exposed to hypoxia, TGZ-induced vasodilation in human 
myometrial arteries was not affected by HA exposure (unpublished data). Further investigation 
is necessary to determine whether disparities in results are due to a different chosen artery, 
technical differences, or biological differences in mouse vs. human vasoregulation. The studies 
presented provide justification for consideration of both AMPK and PPARg pathways in 
identifying therapies for preventing hypoxia-induced fetal growth restriction. Thus, further work 
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